Bausch Health Companies Inc. (BHC) 2019 Q2 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good morning and welcome to the Bausch Health Second Quarter 2019 Earnings Conference Call. (Operator Instructions) Please note this event is being recorded.

    早安,歡迎參加 Bausch Health 2019 年第二季財報電話會議。(接線員指示) 請注意,本活動將被錄音。

  • I would now like to turn the conference over to Art Shannon, Senior Vice President, Investor Relations & Global Communications. Please go ahead.

    現在我想把會議交給投資人關係與全球傳播資深副總裁 Art Shannon。請開始。

  • Arthur J. Shannon - Senior VP and Head of IR & Communications

    Arthur J. Shannon - Senior VP and Head of IR & Communications

  • Thank you, Andrew. Good morning, everyone, and welcome to our second quarter 2019 financial results conference call. Participating on today's call are Chairman and Chief Executive Officer, Mr. Joe Papa; and Chief Financial Officer, Mr. Paul Herendeen. In addition to live this webcast, a copy of today's slide presentation and a replay of this conference call will be available on our website under the Investors Relations section.

    謝謝你,Andrew。各位早安,歡迎參加我們 2019 年第二季財務結果電話會議。今天參與電話會議的有董事長兼執行長 Joe Papa 先生,以及財務長 Paul Herendeen 先生。除本次網路直播外,今日簡報投影片的副本以及本次電話會議的重播,將可於我們網站「投資人關係」專區取得。

  • Before we begin, we would like to remind you that our presentation today contains forward-looking information. We would ask that you take a moment to read the forward-looking statement legend at the beginning of our presentation as it contains important information. This presentation contains non-GAAP financial measures. For more information about these measures, please refer to Slide 2 of the presentation. Non-GAAP reconciliations can be found in the appendix to the presentation posted on our website. Finally, the financial guidance in this presentation is effective as of today only. It is our policy to generally not update guidance until the following quarter and not to update or affirm guidance other than through broadly disseminated public disclosure.

    在開始之前,我們想提醒各位,我們今天的簡報包含前瞻性資訊。請各位花一點時間閱讀簡報開頭的前瞻性聲明說明,因其包含重要資訊。本簡報包含非 GAAP 財務衡量指標。關於這些指標的更多資訊,請參閱簡報第 2 頁。非 GAAP 調節表可於我們網站所發布之簡報附錄中查閱。最後,本簡報中的財務指引僅以今日為準。依公司政策,我們通常不會在下一季之前更新指引,且除透過廣泛公開揭露外,不會更新或確認指引。

  • With that, it's my please to turn the call over to Joe.

    接下來,我很高興把電話會議交給 Joe。

  • Joseph C. Papa - CEO & Chairman of the Board

    Joseph C. Papa - CEO & Chairman of the Board

  • Thank you, Art, and thank you, everyone, for joining us today. I'll begin with the second quarter highlights before turning the call over to Paul Herendeen, our CFO, to review the financial results in detail and update our 2019 guidance. We'll then review the segment highlights and our positioning for the future and how we plan to drive long-term shareholder value before we open the line for questions.

    謝謝你,Art,也謝謝各位今天加入我們。我將先說明第二季重點,接著把電話交給我們的財務長 Paul Herendeen,請他詳細回顧財務結果並更新我們 2019 年的指引。之後我們將回顧各事業部門的重點、我們對未來的布局,以及我們計畫如何推動長期股東價值,最後再開放提問。

  • Beginning with Slide 4. Our strong second quarter results demonstrate that our team's efforts to pivot to offense continue to gain traction. With 3% organic revenue growth, second quarter 2019 was the 6th consecutive quarter of total company organic revenue growth. B+ L/International and Salix which now represent 80% of our total revenue, grew organically by 6% on a combined basis. This was B+ L/International's 11th consecutive quarter of organic revenue growth, and Salix reported more than $500 million in total quarterly revenue for the first time. Our most important products or our top 10 products grew organically by 13% in the aggregate compared to the second quarter of 2018. And our continued focus on improving operational efficiency through Project CORE is expected to deliver more than $75 million of operating profit during 2019.

    先從第 4 頁投影片開始。我們強勁的第二季表現顯示,團隊將策略轉向進攻的努力持續取得進展。在 3% 的有機營收成長下,2019 年第二季是全公司連續第 6 季達成有機營收成長。B+L/International 與 Salix(目前合計占我們總營收的 80%)合併計算的有機成長為 6%。這是 B+L/International 連續第 11 季有機營收成長,而 Salix 也首次單季總營收突破 5 億美元。我們最重要的產品(亦即前 10 大產品)合計有機成長 13%,相較於 2018 年第二季。此外,我們持續透過 CORE 專案聚焦提升營運效率,預期在 2019 年可帶來超過 7,500 萬美元的營業利益。

  • Moving over to the right of Slide 4, TRULANCE, a constipation IBS treatment that we acquired last quarter is off to a great start. It generated $17 million of revenue in its first full quarter since our acquisition. We've continued to launch new products as well, including LOTEMAX SM in April, DUOBRII and ULTRA Multifocal lenses in June, and our Ocuvite Eye Performance vitamins in July. Finally, we continue to strategically manage debt and allocate capital.

    再看第 4 頁投影片右側,TRULANCE 是我們上季收購的便祕與 IBS 治療藥物,開局表現非常亮眼。自收購後的第一個完整季度即創造 1,700 萬美元營收。我們也持續推出新產品,包括 4 月推出 LOTEMAX SM、6 月推出 DUOBRII 與 ULTRA 多焦點鏡片,以及 7 月推出 Ocuvite Eye Performance 眼部維他命。最後,我們持續以策略方式管理負債並配置資本。

  • We generated $339 million of cash from operations during the quarter. We increased R&D spend by approximately 24% in the second quarter. We refinanced $1.5 billion of 2023 senior unsecured notes. And year-to-date as of August 6, we have used $550 million to reduce the debt by approximately $350 million; complete the acquisitions of TRULANCE and dolcanatide; and licensed amiselimod for development and commercialization. Overall, a very strong quarter, thanks to a great team effort and the continued engagement of 21,000 employees of our health companies who are to truly motivated to launch new products, improve operations and keep delivering on commitment to help improve patients’ lives.

    本季我們由營運活動產生 3.39 億美元現金。第二季研發支出約增加 24%。我們為 15 億美元、2023 年到期的優先無擔保票據完成再融資。截至 8 月 6 日的年初至今,我們已動用 5.5 億美元,用以將債務減少約 3.5 億美元;完成 TRULANCE 與 dolcanatide 的收購;並取得 amiselimod 的授權以進行開發與商業化。整體而言,這是一個非常強勁的季度,歸功於優秀的團隊合作,以及我們健康事業群 21,000 名員工持續投入、真正充滿動力地推出新產品、改善營運,並持續履行我們協助改善病患生活的承諾。

  • With that, I'll turn it over to Paul.

    接下來我把電話交給 Paul。

  • Paul S. Herendeen - Executive VP & CFO

    Paul S. Herendeen - Executive VP & CFO

  • Thanks, Joe. Turn to Slide 5, and I'll start by walking down the top level P&L and I'll provide some color around our results. As Joe said, we had a good solid quarter with 1% reported revenue growth and 3% organic growth versus Q2 of 2018. Adjusted EBITDA for the quarter was $880 million, up 1% compared with Q2 of 2018. So we put a good first half on the board and we are raising our revenue and adjusted EBITDA guidance. More on that later. Assuming FX stays where we are today, at the midpoint of our revised guidance, we report about 1% revenue growth for the full year of 2019 versus '18. That's pretty good considering the $180 million growth drag from LOEs we've absorbed in the first half of the year and the expected $213 million expected in the second half. So 3% organic revenue growth overall versus Q2 2018 with 2% of that coming from net price and 1% from volume, that's company-wide.

    謝謝,Joe。請翻到第 5 頁投影片,我將先從損益表的高層次項目逐一說明,並補充一些關於我們結果的背景。如 Joe 所說,我們本季表現穩健,營收按報告基礎年增 1%,相較 2018 年第二季的有機成長為 3%。本季調整後 EBITDA 為 8.80 億美元,較 2018 年第二季增加 1%。因此我們上半年交出不錯的成績,我們也上調營收與調整後 EBITDA 指引。稍後會再說明。假設匯率維持在今日水準,以我們修訂後指引的中位數來看,2019 全年相較 2018 年的營收約成長 1%。考量到我們在上半年已吸收因專利到期(LOEs)造成的 1.80 億美元成長拖累,以及下半年預期還有 2.13 億美元的影響,這樣的表現相當不錯。因此,整體公司相較 2018 年第二季的有機營收成長為 3%,其中 2% 來自淨價格、1% 來自銷量。

  • Salix led the way up 12% organically despite the loss of exclusivity from UCERIS. B+ L/International continued its string of organic growth quarters up 4% with 4 of the 5 subsegments posting growth. Ortho Derm declined 13% organically mainly due to LOEs, while Diversified declined 7% organically. Company-wide adjusted gross margin improved by some 50 basis points versus Q2 of 2018 with approximately 30% of that improvement coming from better operating efficiency in our global supply chain. I'll give a tip of the hat here to the Dennis Asharin and his team for that. And the balance of that improvement was from a shift in mix to higher-margin products.

    Salix 表現領先,即使 UCERIS 失去獨家權,仍有機成長 12%。B+L/International 延續其有機成長的季度表現,上升 4%,五個子事業中有四個呈現成長。Ortho Derm 有機下滑 13%,主要因專利到期(LOEs)所致;Diversified 則有機下滑 7%。全公司調整後毛利率較 2018 年第二季提升約 50 個基點,其中約 30% 的改善來自我們全球供應鏈更佳的營運效率。在此我要向 Dennis Asharin 及其團隊致敬。其餘的改善則來自產品組合轉向毛利較高的產品。

  • Adjusted selling, advertising and promotion expense increased $20 million on a reported basis, with the biggest drivers being the addition of the 100 sales reps and associated promotional spend in connection with the TRULANCE acquisition in the Salix segment and increased spend in B+L/International to support growth products, including LUMIFY, our eye vitamins Ocuvite and PreserVision, Biotrue ONEday and our ULTRA lenses.

    調整後銷售、廣告與促銷費用按報告基礎增加 2,000 萬美元,主要驅動因素包括:在 Salix 事業部因 TRULANCE 收購而新增 100 名業務代表及相關促銷支出;以及在 B+L/International 增加支出以支持成長型產品,包括 LUMIFY、我們的 Ocuvite 與 PreserVision 眼部維他命、Biotrue ONEday,以及 ULTRA 鏡片。

  • Adjusted G&A was down $10 million or 6% on a reported basis, mainly due to reduced corporate support costs, offset a bit by an increase in our IT costs. Our Chief Information Officer, Chuck Hoyt and his team are underway in the process of transforming our global IT systems and infrastructure to support our future growth.

    調整後一般及行政費用(G&A)按報告基礎減少 1,000 萬美元或 6%,主要因公司層級支援成本降低,但部分被 IT 成本增加所抵銷。我們的資訊長 Chuck Hoyt 及其團隊正著手推動全球 IT 系統與基礎架構的轉型,以支持未來成長。

  • R&D was up $23 million or 24% on a reported basis, as we continue to build out our R&D organization and construct a portfolio of projects under development to protect our existing product franchises and to provide the fuel for longer-term growth. A quick note on how R&D appears in our segment P&Ls. R&D shown in the segment P&L reflects only the direct cost directly associated with those segments, mainly external clinical costs. To help you think about how you might allocate R&D to the segments, here is a couple of factoids for you.

    研發(R&D)按報告基礎增加 2,300 萬美元或 24%,因我們持續擴建研發組織,並建立一系列開發中專案組合,以保護既有產品系列,並為更長期的成長提供動能。簡要說明研發在各事業部損益表中的呈現方式。事業部損益表中所列示的研發,僅反映與該事業部直接相關的直接成本,主要是外部臨床費用。為協助各位思考如何將研發費用分配至各事業部,這裡提供幾個小重點。

  • Our 2019 guidance suggest company-wide R&D will be in the range of 5.3% to 5.4% of revenue. As we look forward and think about how our current level of spending in R&D as a percent of revenue might be allocated across our segments in the future, B+ L/International may be at roughly the company-wide average as a percent of revenue; Salix may be higher than that; Ortho Derm less than that and Diversified much less than that. That could change as we evolve but based on where we are today, I think that color might be helpful. So despite the increased selling, advertising and promotion expense to support growth brands and higher R&D costs, our adjusted EBITDA rose 1% on both a reported and constant currency basis. That's good stuff.

    我們對2019年的指引顯示,全公司研發(R&D)將約占營收的5.3%至5.4%。展望未來並思考目前研發支出占營收比重在未來可能如何在各事業部間分配,B+L/International 可能大致接近全公司平均的營收占比;Salix 可能高於該水準;Ortho Derm 低於該水準,而 Diversified 則遠低於該水準。隨著我們演進,這些可能會改變,但就我們目前所處的位置而言,我認為這樣的說明可能會有所幫助。因此,儘管為支持成長品牌而增加了銷售、廣告與促銷費用,以及更高的研發成本,我們的調整後 EBITDA 在報告基礎與固定匯率基礎下均上升1%。這很不錯。

  • While we continue to believe that adjusted EBITDA is our most important profitability performance indicator, I know that some of you also focus on adjusted net income and there are couple of items of note below the operating line. First, as we continue to use available cash to reduce debt, then predictably, interest expense declines and act as kind of adjusted net earnings accelerator. It's the P&L manifestation of the enterprise value shift from debt to equity every time we reduce our debt. From Q2 of 2018 to '19, our interest expense declined $26 million. The other item of note is our income tax rate on adjusted earnings, roughly 8% this quarter versus 12% in Q2 of 2018. The combination of those 2 items result in adjusted net income being up 13% on a constant currency basis in Q2 '19 versus Q2 of 2018.

    雖然我們仍然相信調整後 EBITDA 是我們最重要的獲利表現指標,但我知道你們之中也有人關注調整後淨利,而在營業利益線以下有幾個值得注意的項目。首先,隨著我們持續使用可用現金降低負債,利息費用可預期地下降,並在某種程度上成為調整後淨利的加速器。這是每當我們降低負債時,企業價值從負債轉向股權的損益表(P&L)呈現。從2018年第二季到2019年第二季,我們的利息費用下降了2,600萬美元。另一個值得注意的項目是我們調整後盈餘的所得稅率,本季約為8%,而2018年第二季為12%。這兩項因素的組合,使得2019年第二季相較2018年第二季,在固定匯率基礎下的調整後淨利成長13%。

  • Turning quickly to the segments and starting with the B+ L/International on Slide 6. The 4% organic growth was driven by 1% by price and 3% by volume. Just a couple of items of note. In terms of dollar contribution of growth, the Global Consumer business was up a solid 5% organically on strong sales of our eye vitamins PreserVision and Ocuvite and our redness reliever LUMIFY. The growth in consumer was all volume-driven as realized prices were down slightly. Global Vision Care was very strong, plus 8% organically, the 8th consecutive quarter of growth for the Global Vision Care business. The growth dollars in Global Vision Care came roughly equally from within the U.S. and internationally. Growth in Global Vision Care was all volume as realized net pricing was flat that's across the segment. Note that in the U.S. over the last couple of years, we have been using discounting strategically while partnering with independent optometrists and eye care retailers, and that was to regain momentum and increase share. It's working and under Joe Gordon's vatic leadership, the U.S. Vision Care business has grown in dollar curve for 8 consecutive quarters.

    快速轉到各事業部,先看第6頁的 B+L/International。4%的有機成長中,1%來自價格、3%來自銷量。有幾點值得注意。就成長的金額貢獻而言,全球消費者業務在 PreserVision 與 Ocuvite 眼部維他命,以及我們的去紅血絲產品 LUMIFY 強勁銷售帶動下,有機成長穩健達5%。消費者業務的成長完全由銷量驅動,因為實現價格略有下降。全球視力保健(Global Vision Care)表現非常強勁,有機成長8%,這也是全球視力保健業務連續第8個季度成長。全球視力保健的成長金額貢獻,大致由美國與國際市場各占一半。全球視力保健的成長完全來自銷量,實現淨價格持平——這是整個事業部的情況。請注意,在美國過去幾年,我們在與獨立驗光師及眼科零售商合作的同時,策略性地運用折扣,以重拾動能並提升市占。這項策略正在奏效,在 Joe Gordon 的卓越領導下,美國視力保健業務已連續8個季度在金額曲線上成長。

  • We've ratcheted back our use of discounting and in Q2 of 2019 versus '18, our realized net pricing in the U.S. decreased only slightly versus Q2 of '18 while volume was up significantly, good stuff indeed. The growth drivers in the segment for the quarter were the Biotrue ONEday family, our silicone hydrogel daily disposable, AQUALOX in Japan and our ULTRA family of silicone hydrogel lenses, particularly outside the United States.

    我們已降低折扣的使用,而在2019年第二季相較2018年第二季,美國的實現淨價格僅小幅下降,但銷量顯著上升,確實很不錯。本季該事業部的成長動能來自 Biotrue ONEday 系列、我們的矽水膠日拋產品、日本的 AQUALOX,以及我們的 ULTRA 系列矽水膠鏡片,尤其是在美國以外的市場。

  • Our international pharma business grew 4% organically which benefited from solid performance mainly in Canada, Eastern Europe, and in the Middle East and that was mainly Amoun in Egypt. Global Ophtho declined 1% organically, impacted by a decline in LOTEMAX due to loss of exclusivity that was offset by VYZULTA growth and strong performance in international markets. Global Surgical grew 2% organically, driven mainly by growth in our international businesses outside the U.S. Down in operating expenses for B+ L/International, you can see the increase in selling, advertising, and promotion expenses that I talked about earlier.

    我們的國際製藥業務有機成長4%,受惠於主要在加拿大、東歐與中東的穩健表現,而中東主要來自埃及的 Amoun。全球眼科(Global Ophtho)有機下滑1%,主要受 LOTEMAX 因失去獨占性而下滑影響,但部分被 VYZULTA 的成長以及國際市場的強勁表現所抵銷。全球外科(Global Surgical)有機成長2%,主要由美國以外的國際業務成長所帶動。回到 B+L/International 的營業費用,你可以看到我先前提到的銷售、廣告與促銷費用增加。

  • On to Salix Slide 7. Salix was up 12% organically, that's excluding the $17 million of revenue from TRULANCE that was acquired earlier this year. XIFAXAN was a star, up 21% overall. Volume was up 8%, that's in line with the growth in TRxs, improved gross net spreads -- excuse me, gross to net associated with our Project CORE added about another 7%, and the net impact of the January price increase after the associated contractual increases in rebates added another plus 6%. The flow-through benefits of our Project CORE activities on XIFAXAN that have improved our gross to net for the brand will likely be a bit of a growth tailwind through Q3 of this year, but I expect them to moderate in Q4 and beyond.

    接著看第7頁的 Salix。Salix 有機成長12%,此數字不包含今年稍早收購的 TRULANCE 所帶來的1,700萬美元營收。XIFAXAN 表現亮眼,整體成長21%。銷量成長8%,與處方量(TRxs)的成長一致;我們的 Project CORE 改善了毛利到淨額(gross to net)——抱歉,是與 Project CORE 相關的毛利到淨額改善——另外貢獻約7%;而1月調價在相關合約性回扣增加後的淨影響,則再增加約6%。我們在 XIFAXAN 上推動的 Project CORE 活動所帶來的滲透效益,已改善該品牌的毛利到淨額,這些效益在今年第三季可能仍會對成長形成些許順風,但我預期在第四季及之後會趨於溫和。

  • Glumetza has continued to do well despite the loss of exclusivity for the brand. Our proactive management of the brand through that loss of exclusivity resulted in our seeing excellent realized net pricing in the quarter and a marked uptick in volume. A word of caution here with respect to Glumetza. As we move into the back half of 2019, we fully expect a significant drop in realized net pricing for Glumetza, especially in Q4 and beyond. Down in Salix operating expenses, you see the impact of the acquisition of TRULANCE in the 29% increase in selling, advertising and promotion expenses.

    儘管該品牌已失去獨占性,Glumetza 仍持續表現良好。我們在失去獨占性期間對該品牌的主動管理,使我們在本季看到極佳的實現淨價格,以及銷量明顯回升。在此對 Glumetza 提醒一點。隨著進入2019年下半年,我們完全預期 Glumetza 的實現淨價格將大幅下滑,尤其是在第四季及之後。在 Salix 的營業費用方面,你會看到收購 TRULANCE 的影響,反映在銷售、廣告與促銷費用增加29%。

  • On to Ortho Dermatologics in Slide 8. Overall segment revenue was down 13%, as it continued and I would say, impressive growth of Solta could not overcome the impacts of LOEs in the medical derm business. In Solta, as we rolled out Thermage FLX in the Asia Pac, the demand was even stronger than we had forecasted and was a big driver of the 44% organic growth over Q2 of 2018. In medical derm, the $36 million impact of LOEs, including for ELIDEL, SOLODYN, and ZOVIRAX overwhelmed the $4 million pickup in the balance of the portfolio.

    接著看第8頁的 Ortho Dermatologics。整體事業部營收下滑13%;雖然 Solta 持續、我會說相當亮眼的成長,但仍無法抵銷醫療皮膚科業務因失去獨占性(LOEs)所帶來的影響。在 Solta,隨著我們在亞太地區推出 Thermage FLX,需求甚至比我們預期更強,成為相較2018年第二季有機成長44%的主要推動力。在醫療皮膚科方面,包含 ELIDEL、SOLODYN 與 ZOVIRAX 在內的 LOEs 造成3,600萬美元的影響,遠超過產品組合其餘部分增加的400萬美元。

  • Turning to Slide 9 in the Diversified segment. Our generics business benefited from launches of authorized generic versions of UCERIS and ELIDEL, and our team continue to capitalize on competitive supply issues. Our dentistry business continues to face reimbursement challenges from payers particularly for Arestin and our neurology business absorbed an LOE impact of $30 million versus Q2 of 2018. As a reminder, our Diversified segment is not expected to grow. We manage the assets in the segment to maximize cash flows over time and the 7% decline in revenue for the quarter is consistent with that goal. Note that we selectively promote some of the products in this segment where we believe that the durability and duration of the brands enables us to earn appropriate returns on those promotional investments. I'm talking about products like Wellbutrin, Aplenzin and Migranal. You see that at selling, advertising and promotion expense increased versus Q2 of 2018, that's why. I'd say these activities aren't as high profile as say, promoting XIFAXAN or LUMIFY but they are value generative nevertheless. For example, Aplenzin was up 62% compared with Q2 of 2018. The neuro business had been run by a talented colleague named Yolande Barnard and she delivered excellent results for us. And that earned her the shot to move over and now head our U.S. Ophtho Rx business.

    接著看多元化事業部的第 9 張投影片。我們的學名藥業務受惠於 UCERIS 與 ELIDEL 授權學名藥版本的上市推出,而我們的團隊也持續把握競爭對手供應問題所帶來的機會。我們的牙科業務仍持續面臨付款方(特別是針對 Arestin)的給付挑戰,而我們的神經科業務相較於 2018 年第二季吸收了 3,000 萬美元的專利到期(LOE)影響。提醒一下,我們的多元化事業部預期不會成長。我們管理該事業部的資產,以在時間推移中最大化現金流,而本季營收下滑 7% 與此目標一致。請注意,我們會選擇性地推廣該事業部中的部分產品,因為我們相信品牌的耐久性與存續期間,使我們能在這些推廣投資上獲得適當報酬。我指的是像 Wellbutrin、Aplenzin 與 Migranal 這類產品。你會看到銷售、廣告與推廣費用相較於 2018 年第二季有所增加,原因就在這裡。我會說,這些活動不像推廣 XIFAXAN 或 LUMIFY 那樣高調,但仍然能創造價值。例如,Aplenzin 相較於 2018 年第二季成長了 62%。神經科業務一直由一位才華洋溢的同事 Yolande Barnard 負責,她為我們交出了非常出色的成果。而這也讓她獲得機會轉任,並且現在領導我們美國眼科處方藥(Ophtho Rx)業務。

  • On to the balance sheet on Slide 10. If you look at the balance sheet from the end of 2018 to June 30, 2019, year-to-date, we reduced total debt by some $250 million. I'll point out that we also played -- recently paid down another $100 million of our debt. So year-to-date to today, debt reduction in 2019 is roughly $350 million.

    接著看第 10 張投影片的資產負債表。如果你比較 2018 年底到 2019 年 6 月 30 日的資產負債表,截至目前(年初至今),我們將總負債降低了約 2.5 億美元。我也要指出,我們最近又償還了另外 1 億美元的債務。因此,2019 年截至今天,減債金額約為 3.5 億美元。

  • Turning to Slide 11 in our cash flow. Our cash provided by operating activities in Q2 totaled $339 million. This was higher than we expected due to some serendipity in the timing of cash receipts at the end of the quarter. I'm bringing this up because we said in the past that Q2 and Q4 are expected to be weaker cash generation quarters due to the clustering of inter-settlement dates in those two quarters. About 1/3 of our cash interest settles in each of Q2 and Q4 and about 1/6 in Q1 and Q3. The higher cash generated in Q2 due to the fortunate timing of cash receipts will take the top off to some of our cash generation in Q3, but we are still on track to generate between $1.5 billion and $1.6 billion in cash from operating activities in 2019.

    接著看第 11 張投影片的現金流。我們第二季來自營運活動的現金流入合計為 3.39 億美元。由於季末現金收款時點上的一些偶然因素,這比我們預期更高。我特別提出這點,是因為我們過去曾表示,第二季與第四季預期會是現金創造較弱的季度,原因在於這兩個季度的結算日較為集中。我們約有 1/3 的現金利息在第二季與第四季各自結算,第一季與第三季各約為 1/6。第二季因收款時點有利而產生的較高現金,將會在一定程度上降低第三季的現金創造,但我們仍按計畫在 2019 年由營運活動產生 15 億至 16 億美元的現金。

  • On to guidance on Slide 12. We are raising our revenue guidance by $50 million across the range and for adjusted EBITDA by $25 million across the range. Most of the other guidance are unchanged, except that we revised our guidance for gross margin to roughly 72% based on where we are at the halfway point and we increased the estimate for share-based comp to $110 million.

    接著看第 12 張投影片的財測指引。我們將營收指引區間整體上調 5,000 萬美元,並將調整後 EBITDA 指引區間整體上調 2,500 萬美元。其他大多數指引維持不變,唯獨我們依據目前過半進度,將毛利率指引修訂至約 72%,並將以股份為基礎的薪酬估計提高至 1.1 億美元。

  • On Slide 13, you see the guidance bridge. Since we last provided guidance back in May, FX improved at the revenue level by $10 million. We increased our expectation for revenues for the LOE assets by $20 million and increased our expectations for our base business by $20 million. The change in the LOE estimate was based on our moving out the date for APRISO to Q4. At adjusted EBITDA, we raised guidance by $25 million across the range and that was driven by $10 million of incremental profit from the LOE assets and improved profitability in our base business.

    在第 13 張投影片,你會看到指引橋接表。自我們上次在 5 月提供指引以來,匯率(FX)在營收層面改善了 1,000 萬美元。我們將 LOE 資產的營收預期上調 2,000 萬美元,並將基礎業務的營收預期也上調 2,000 萬美元。LOE 估計的變動,係因我們將 APRISO 的日期延後至第四季。在調整後 EBITDA 方面,我們將指引區間整體上調 2,500 萬美元,主要由 LOE 資產帶來的額外 1,000 萬美元利潤,以及基礎業務獲利能力改善所驅動。

  • Before I turn it back to Joe, I think it's worth taking a stock of where we are today and how we are positioned for the future. We made significant progress in reducing the quantum of our debt, we're down some $8 billion since Q1 of '16 and in managing our upcoming maturities. As Joe loves to say, "That gave us the freedom to operate to put our company on the right path." We have now posted 6 consecutive quarters of organic revenue growth, which considering the sheer volume of LOEs we've had to work through is quite an accomplishment. We've laid the foundation to enable the company to capitalize on its competitive strengths and deliver consistent growth of organic revenue, profits, and cash flow. That started with reorganizing our businesses and putting in place a strong commercial leadership team. Then we took a hard look at our operating expenses, eliminated the ineffective costs and allocated additional resources where we could drive growth.

    在我把時間交回給 Joe 之前,我認為值得盤點一下我們目前的狀況,以及我們如何為未來做好布局。我們在降低債務規模方面取得重大進展,自 2016 年第一季以來已減少約 80 億美元,並且也在管理即將到期的債務。正如 Joe 常說的:「這讓我們有了自由去運作,讓公司走在正確的道路上。」我們現在已連續 6 個季度實現有機營收成長,考量到我們必須消化的 LOE 數量之龐大,這是相當了不起的成就。我們已奠定基礎,使公司能夠發揮其競爭優勢,並持續帶來有機營收、獲利與現金流的穩健成長。這始於我們重整業務並建立強而有力的商業領導團隊。接著我們嚴格檢視營運費用,刪除無效成本,並在能夠推動成長之處配置更多資源。

  • To ensure that we can grow organically, we've increased our spend in R&D. So today, with the great progress we've made in dealing with our capital structure and with the magnitude of the LOE impacts decreasing, we believe that we are a company that can grow at mid-single-digit rates over time, is highly diversified with positions of competitive strength in each of our core businesses, and enjoys an efficient global tax structure that enables us to convert a large percentage of earnings into cash that can be used to shift the enterprise value from our debt holders to our equity holders.

    為了確保我們能夠實現有機成長,我們提高了研發(R&D)支出。因此,基於我們在處理資本結構方面所取得的重大進展,以及 LOE 影響幅度正在下降,我們相信公司長期可望以中個位數的速度成長;在各核心業務中皆具備具競爭力的優勢地位且高度多元化;並享有高效率的全球稅務架構,使我們能將相當高比例的盈餘轉換為現金,用以將企業價值由債權人轉移至股東。

  • We've come a long way since 2016. Joe?

    自 2016 年以來,我們已走了很長一段路。Joe?

  • Joseph C. Papa - CEO & Chairman of the Board

    Joseph C. Papa - CEO & Chairman of the Board

  • Thank you, Paul. Another great review. Let's go through some of the highlights in our B+ L/International segment on Slide 14. First, this segment delivered 4% organic growth as you can see in the chart. The second quarter's organic growth was driven by an increase in volume particularly in Global Consumer and Global Vision Care. And looking ahead to future growth drivers for this business, we believe there are mega trends that have the potential to drive demand for eye care products in the years ahead. One of these mega trends, myopia or nearsightedness is increasing to an epidemic level. Importantly, myopia is also a risk factor for glaucoma, macular degeneration and retinal detachment. And this, unfortunately, is a global trend.

    謝謝你,Paul。又一次很棒的回顧。讓我們在第 14 張投影片中,回顧 B+L/國際事業部的一些重點。首先,如圖表所示,該事業部實現了 4% 的有機成長。第二季的有機成長主要由銷量增加所帶動,尤其是在全球消費者(Global Consumer)與全球視力保健(Global Vision Care)方面。展望未來的成長動能,我們相信存在一些「巨型趨勢」(mega trends),有潛力在未來數年推動眼部護理產品的需求。其中之一是近視(myopia),也就是視力短視,正以流行病等級的速度增加。重要的是,近視同時也是青光眼、黃斑部退化與視網膜剝離的風險因子。而不幸的是,這是一個全球性的趨勢。

  • Nearly 40% of North Americans are now affected by myopia and the number of cases have doubled between 1972 and 2004. In Europe, 42% of adults between the age of 25 to 29 have myopia, almost twice the rate of the 55- to 59-year-olds. And we're seeing a similar trend in Eastern Asia. 87% of individuals born after 1997 in Hong Kong have myopia compared to 30% born prior to 1950. Bausch + Lomb's integrated eye care platform is well positioned, provides products to improve the lives of those with myopia, including corrective lenses, over-the-counter ophthalmic products, surgical offerings, and prescription treatments.

    目前北美地區近 40% 的人口受到近視影響,且病例數在 1972 年至 2004 年間增加了一倍。在歐洲,25 至 29 歲的成年人中有 42% 近視,幾乎是 55 至 59 歲族群的兩倍。我們在東亞也看到類似趨勢。香港 1997 年後出生者中有 87% 近視,相較之下,1950 年前出生者為 30%。Bausch + Lomb 的整合式眼部護理平台具備良好布局,提供多種產品以改善近視患者的生活,包括矯正鏡片、非處方眼科產品、手術產品,以及處方治療方案。

  • Turning now to Global Consumer on Slide 15. Our eye vitamins, Ocuvite and PreserVision, grew by 13% organically in the second quarter on a combined basis, driven by brand extensions. LUMIFY continues to outpace expectations, having achieved a weekly market share of more than 35%, just 1 year after launch. In our redness reliever category, LUMIFY is #1 physician-recommended product and the #1 eye drop on Amazon. E-commerce continues to be an important channel for our Global Consumer products as the second order of Amazon data demonstrates with 83% growth compared to the second quarter of 2018.

    現在轉到第15頁的全球消費者業務。我們的護眼維他命 Ocuvite 與 PreserVision 第二季合計以有機基礎成長13%,主要由品牌延伸產品帶動。LUMIFY 持續超出預期,上市僅1年後,其每週市占率已超過35%。在我們的去紅血絲品類中,LUMIFY 是醫師推薦的第1名產品,也是亞馬遜上的第1名眼藥水。電商仍是我們全球消費者產品的重要通路,正如第二組亞馬遜數據所示,較2018年第二季成長83%。

  • Onto Slide 16, new products are driving 8% organic growth in Vision Care. International, we saw significant growth in Japan, China, and Russia. And in the U.S., Vision Care had its 21st consecutive month of market-leading growth. If you look at the chart on the bottom left, you can see Bausch + Lomb's estimated U.S. contact lens growth of 13% in the second quarter compared to the industry average of approximately 8%. Globally, B + L grew by 8% compared to the industry average of approximately 5%. I want to highlight one new launch product that is helping drive this growth, ULTRA Multifocal contacts for astigmatism. Breaking new ground, this product is the first multifocal toric lens available as a standard offering in fit sets, rather than as a custom order. Now available in the U.S., the ULTRA lenses allow for a seamless transition between distances and given that the limited options for the 32 million people in the U.S. who have both astigmatism and presbyopia, we believe these lenses will have a strong market position and significant growth opportunity.

    接著看第16頁,新產品正推動視力保健(Vision Care)有機成長8%。在國際市場方面,日本、中國與俄羅斯皆出現顯著成長。而在美國,視力保健已連續第21個月維持市場領先的成長。若看左下方圖表,可見 Bausch + Lomb 估計其美國隱形眼鏡第二季成長13%,相較於產業平均約8%。在全球範圍內,B + L 成長8%,相較於產業平均約5%。我想特別強調一項有助於推動此成長的新上市產品:ULTRA Multifocal 散光多焦點隱形眼鏡。此產品開創新局,是首款可在驗配試戴組(fit sets)中以標準品提供的散光多焦點鏡片,而非以客製訂單方式供應。ULTRA 鏡片目前已在美國上市,可在不同距離間提供順暢的視覺轉換;鑑於美國約有3,200萬人同時有散光與老花、且可選擇方案有限,我們相信這些鏡片將具備強勢的市場定位與顯著的成長機會。

  • Turning now to Slide 17. Salix had a great quarter, delivering over $500 million of revenue for the first time, driven by XIFAXAN which had its highest quarterly reported revenue to date. Compared to the prior year quarter, TRx for our promoted brands all grew nicely in the second quarter. XIFAXAN was up 8%. TRULANCE grew by 31%, and RELISTOR oral was up 12%.

    現在轉到第17頁。Salix 本季表現亮眼,營收首次突破5億美元,主要由 XIFAXAN 帶動,且其季度申報營收創下歷史新高。與去年同期相比,我們重點推廣品牌在第二季的 TRx(總處方量)皆有不錯成長。XIFAXAN 成長8%。TRULANCE 成長31%,RELISTOR 口服劑型成長12%。

  • Our team also resolved two important intellectual property matters. The court upheld the validity in terms that Actavis infringed our patent protecting RELISTOR tablets, and we resolved the APRISO IP litigation with 2 out of the 4 Paragraph IV filers. Finally, we anticipate some near-term developments that are expected to be catalyst for this business. These includes 3 new indication development programs for rifaximin and a cardiovascular Holter readout for amiselimod that we are expecting around the year end.

    我們的團隊也解決了兩項重要的智慧財產權事項。法院維持專利有效,並認定 Actavis 侵害了我們保護 RELISTOR 錠劑的專利;同時,我們也與4家 Paragraph IV 申請者中的其中2家,就 APRISO 的智慧財產權訴訟達成解決。最後,我們預期短期內將出現一些進展,預計會成為推動此業務的催化劑。其中包括利福昔明(rifaximin)的3項新適應症開發計畫,以及我們預計在年底前後取得 amiselimod 的心血管 Holter 讀出結果。

  • On the right, we show our approach to expanding and diversifying the GI business at the base of our portfolio of promoted products, including TRULANCE which we recently acquired. Building on that base, the sales team has had a number of additional initiatives that we expect to help grow this business over the longer-term, including new indications for rifaximin, amiselimod, which is a S1P modulator for the treatment of ulcerative colitis; dolcanatide, an investigational compound, which has demonstrated proof-of-concept in treating multiple GI conditions; an investigational treatment for NASH; and finally, an over-the-counter probiotic. Overall, we are pleased with the progress in our GI pipeline and we're looking forward to a lot of activity over the next 12 months.

    右側展示了我們擴大並多元化腸胃(GI)業務的方法:以我們已推廣產品組合的基礎為核心(包括我們近期收購的 TRULANCE)。在此基礎之上,銷售團隊也推動多項額外計畫,預期將在較長期協助擴大此業務,包括:利福昔明的新適應症、amiselimod(用於治療潰瘍性結腸炎的 S1P 調節劑)、dolcanatide(研究中化合物,已在多種腸胃疾病治療上展現概念驗證)、一項針對 NASH 的研究中療法,以及最後的非處方益生菌。整體而言,我們對腸胃領域研發管線的進展感到滿意,並期待未來12個月將有大量活動。

  • I want to talk some more about XIFAXAN on Slide 18 given its record quarter of 21% reported revenue growth. As Paul discussed earlier, this growth was primarily driven by volume and proactive steps to improve gross to net. We're seeing strong script growth with TRxs up 8% versus the second quarter 2018 and up 6% versus just the first quarter sequential of 2019. The primary care field expense is delivering. New Rxs in primary care grew by 16% in the second quarter versus the prior year quarter. You can see the quarterly TRx trend on the right, which shows the TRx growth since the primary care team was added in the first quarter of 2017. And in the second quarter of 2019, XIFAXAN was up approximately 13% in the non-retail channel, compared to the prior year quarter.

    鑑於 XIFAXAN 本季創紀錄、申報營收成長21%,我想在第18頁再多談一些。如 Paul 先前所述,此成長主要由用量增加,以及主動改善 gross-to-net(毛額到淨額)所帶動。我們看到處方量成長強勁:TRx 較2018年第二季成長8%,較2019年第一季按季成長6%。基層醫療(primary care)外勤費用的投入正在產生效果。第二季基層醫療的新處方(New Rx)較去年同期成長16%。右側可見季度 TRx 趨勢,顯示自2017年第一季加入基層醫療團隊以來的 TRx 成長。而在2019年第二季,XIFAXAN 在非零售通路較去年同期成長約13%。

  • Onto Slide 19, TRULANCE continues to perform well relative to the 2019 guidance we gave last quarter. In the first quarter of promotion since the acquisition, TRULANCE TRxs grew by 31% versus the prior quarter and by 7% over the first quarter. Leveraging Salix existing GI in primary care relationship for TRULANCE, we have further integrated TRULANCE with our largest XIFAXAN sales force. As we've shown on the bottom right, we had about 100 reps detailing TRULANCE in the first quarter. We added another 100 sales reps in the second quarter. And as of this month, we've increased that number to approximately 500 sales reps promoting TRULANCE. We also increased GI and primary care targets by more than 65% in the second quarter and increased reach and frequency to health care providers by more than 60% since the acquisition.

    接著看第19頁,TRULANCE 的表現持續優於我們上季提供的2019年指引。自收購後開始推廣的第一個季度,TRULANCE 的 TRx 較前一季成長31%,並較第一季成長7%。我們運用 Salix 在基層醫療端既有的腸胃領域關係來推動 TRULANCE,並進一步將 TRULANCE 與我們規模最大的 XIFAXAN 銷售團隊整合。如右下所示,第一季約有100位業務代表推廣 TRULANCE。第二季我們再增加100位業務代表。截至本月,我們已將推廣 TRULANCE 的業務代表人數提高至約500人。我們也在第二季將腸胃與基層醫療目標客戶數提高逾65%,並自收購以來將對醫療照護提供者的觸及率與拜訪頻率提高逾60%。

  • Our team has also done an excellent job in improving market access, commercial coverage has increased to approximately 86%, and unrestricted access is right around 47%. We also added 2.4 million covered lives across 5 regional plans since acquisition and improved coverage for roughly 7 million federal lives through the TRICARE program. Overall, we are very pleased with TRULANCE performance.

    我們的團隊也在改善市場准入方面表現出色:商業保險覆蓋率已提升至約86%,而不受限制的准入約為47%。自收購以來,我們也在5個區域性方案中新增了240萬名受保人(covered lives),並透過 TRICARE 計畫改善約700萬名聯邦受保人的覆蓋。整體而言,我們對 TRULANCE 的表現非常滿意。

  • Moving on to Ortho Dermatologics on Slide 20. While we report a total segment organic revenue decline in the second quarter, the performance of our aesthetic business has been outstanding, up 44% organically driven by the strong launch of Thermage FLX. Another highlight is Dermatology.com, our cash paid prescription program which is gaining traction. We recently announced that the program will be available at more than 9,500 Walgreens U.S. retail pharmacy locations by the end of this month. We expect approximately 15 products to be available through the Dermatology.com channel before the year end and to launch e-commerce and telemedicine on the platform in 2020.

    接著看第20頁的 Ortho Dermatologics。雖然我們第二季申報的整體分部有機營收下滑,但醫美業務表現非常出色,有機成長44%,主要由 Thermage FLX 的強勁上市帶動。另一項亮點是 Dermatology.com——我們的自費處方(cash paid prescription)計畫,正逐步獲得市場動能。我們近期宣布,該計畫將於本月底前在美國超過9,500家 Walgreens 零售藥局據點提供。我們預期在年底前,約有15項產品可透過 Dermatology.com 通路取得,並計畫於2020年在該平台上推出電商與遠距醫療(telemedicine)。

  • We see a real opportunity for Ortho Dermatologics to be a leader in delivering predictable access to prescription dermatologies at predictable prices. The segment as a whole, we're pleased that new products in aesthetics are driving the transformation of the dermatology business. You can see the progress we're making on the graphs on the bottom of Slide 20. Here we've shown the percentage of revenue from Global Solta base business in green and new products, including the Thermage FLX, which are shown at the timeline at the bottom of the slide in blue. Beginning in 2017, the revenue from Global Solta generated approximately 15.2% of total segment revenue. In 2018, Global Solta and new products contributed 18.3% and 7.7%, respectively of total segment revenue. And in the first half of 2019, Global Solta revenue had grown to 21.7% and new products generated 23% of total segment revenue. So with nearly half of total segment revenue being driven by Global Solta and newly launched product, we're moving in the right direction and expecting this trend to continue.

    我們看到 Ortho Dermatologics 在以可預期的價格提供可預期的處方皮膚科用藥可近性方面,確實存在成為領導者的機會。就整個事業部而言,我們很高興看到醫美領域的新產品正在推動皮膚科業務的轉型。您可以在第 20 張投影片底部的圖表中看到我們所取得的進展。在這裡,我們以綠色顯示 Global Solta 基礎業務的營收占比,並以藍色顯示新產品(包括 Thermage FLX)的營收占比;這些新產品也在投影片底部的時間軸上以藍色標示。自 2017 年起,Global Solta 的營收約占該事業部總營收的 15.2%。2018 年,Global Solta 與新產品分別貢獻該事業部總營收的 18.3% 與 7.7%。而在 2019 年上半年,Global Solta 的營收占比已成長至 21.7%,新產品則貢獻該事業部總營收的 23%。因此,隨著 Global Solta 與新上市產品合計驅動了接近一半的事業部總營收,我們正朝正確方向前進,並預期此趨勢將持續。

  • On to Slide 21. Early feedback on DUOBRII has been very positive. First and foremost, DUOBRII is a topical treatment you can keep using until your skin is clear, per your health care provider instructions. This is a key differentiator. Many health care providers recognize the benefits of topical products that does not have the duration limitation of other treatments for psoriasis, which is a chronic disease. We're seeing strong momentum and product demand. In the 5th week, post launch, we've delivered more than 1,650 prescriptions.

    接著看第 21 張投影片。DUOBRII 的早期回饋非常正面。首先也是最重要的是,DUOBRII 是一種外用治療,依照醫療照護提供者的指示,您可以持續使用直到皮膚清除為止。這是一項關鍵差異化。許多醫療照護提供者認同,對於乾癬這種慢性疾病而言,不像其他治療有使用期間限制的外用產品具有其優勢。我們看到強勁的動能與產品需求。在上市後第 5 週,我們已開出超過 1,650 張處方。

  • Also, DUOBRII's managed care value proposition is compelling. It has the potential to delay some patients from switching to more expensive biological treatment which could result in an overall health care savings. In terms of reimbursement coverage, DUOBRII has more than 30% of covered lives at launch, and we are projecting approximately 75% of covered lives, 12 months post launch. Based on early data, we remain very optimistic about DUOBRII's potential, when you combine DUOBRII's efficacy as a treatment, with its potential to create significant cost savings for managed care, we believe there is an enormous opportunity for this product.

    此外,DUOBRII 對於受管理式醫療(managed care)的價值主張也很有吸引力。它有潛力延後部分患者轉換至更昂貴的生物製劑治療,從而可能帶來整體醫療支出的節省。就給付涵蓋而言,DUOBRII 在上市時已涵蓋超過 30% 的受保人群(covered lives),我們預估在上市後 12 個月可達約 75% 的受保人群。根據早期數據,我們仍對 DUOBRII 的潛力非常樂觀;當把 DUOBRII 作為治療的療效與其為受管理式醫療創造顯著成本節省的潛力結合起來時,我們相信這項產品存在巨大的機會。

  • Onto Slide 22, I'm happy to report that all of the Significant Seven products have now been launched. And in the first half of 2019, Significant Seven revenue increased by 76% versus the first half of 2018. On Slide 23, we present our perspective and how the company is positioned for future growth and how we plan to drive long-term shareholder value. First, building on the points that Paul made earlier, we continue to improve and derisk our balance sheet. We're reduced debt by approximately $8 billion since the first quarter of 2016, and we are successfully managing our maturity profile. Next is growth. We've overcome the primary loss of exclusivity challenge facing the business and any way you look at it, we are now growing. The second quarter was our 6th constitutive quarter of total company organic growth. Finally, investment. Our growth is not coming at the expense of tomorrow. We are investing in future growth drivers.

    接著看第 22 張投影片,我很高興報告,「重要七項」(Significant Seven)產品如今都已上市。而在 2019 年上半年,重要七項的營收較 2018 年上半年成長 76%。在第 23 張投影片中,我們提出我們的觀點:公司如何為未來成長做好定位,以及我們計畫如何推動長期股東價值。首先,延續 Paul 先前提到的重點,我們持續改善並降低資產負債表風險。自 2016 年第一季以來,我們已將債務降低約 80 億美元,並成功管理我們的到期結構。接下來是成長。我們已克服業務所面臨的主要專利到期/獨占權喪失(LOE)挑戰;不論從哪個角度看,我們現在都在成長。第二季是我們公司整體有機成長連續第 6 個季度。最後是投資。我們的成長並非以犧牲明天為代價。我們正在投資於未來的成長驅動因素。

  • We've increased R&D spend and we're getting new products approved and launched, while also strengthening our new product pipeline through business development. We have invested and continue to invest in sales teams to drive commercial growth. Our XIFAXAN primary care sales team is delivering growth, and we are deploying 500 sales reps behind TRULANCE as a new driver for our Salix business. We are also expanding our psoriasis sales force with SILIQ, BRYHALI, and DUOBRII. And we are continuing to build out Solta's geographic footprint. For these reasons, we believe that Bausch Health is well positioned for the future.

    我們已提高研發支出,並在取得新產品核准與上市的同時,也透過業務開發強化我們的新產品研發管線。我們已投資且持續投資於銷售團隊,以推動商業成長。我們的 XIFAXAN 基層醫療(primary care)銷售團隊正在帶動成長,而我們也在 TRULANCE 這個 Salix 業務的新成長動能上配置 500 名業務代表。我們也正擴編乾癬銷售團隊,涵蓋 SILIQ、BRYHALI 與 DUOBRII。同時,我們持續擴大 Solta 的地理布局。基於這些原因,我們相信 Bausch Health 已為未來做好良好定位。

  • To wrap up, Slide 24 summarizes the expectations for 2019 that we set forth at the beginning of the year. To review: first, we expect to grow both organically on a reported basis; second, we expect strong cash flow for operations; R&D is expected to grow by approximately 10%; the Significant Seven revenue is expected to be double in 2019; Project CORE is expected to deliver more than $75 million operating profit in 2019; and finally, we've raised our guidance for the year.

    最後,第 24 張投影片總結了我們在年初提出的 2019 年預期。回顧如下:第一,我們預期在有機成長與報表口徑(reported basis)兩方面都能成長;第二,我們預期營運將帶來強勁現金流;研發支出預期將成長約 10%;重要七項營收預期在 2019 年將翻倍;Project CORE 預期在 2019 年可帶來超過 7,500 萬美元的營業利益;最後,我們已上調本年度的財測指引。

  • With that operator, let's open up the lines for questions.

    那麼,接線員,我們開放電話線進行提問。

  • Operator

    Operator

  • (Operator Instructions) The first question comes from Chris Schott of JPMorgan.

    (接線員指示) 第一個問題來自摩根大通(JPMorgan)的 Chris Schott。

  • Christopher Thomas Schott - Senior Analyst

    Christopher Thomas Schott - Senior Analyst

  • I guess my first one is can you just talk a little bit more about pathways to further delever the business? I guess it seems to me with the strong organic performance we're seeing and the Alcon's spin shining a light on the B + L business, one of the primary hurdles to your valuation further re-rating is the company's leverage position. So I guess, just how much of a priority is it for the company to find ways to accelerate the deleveraging process beyond just organic growth and do you see pathways to do that?

    我想我的第一個問題是,能否再多談一些進一步降低槓桿(delever)的方法?在我看來,隨著我們看到強勁的有機表現,以及 Alcon 的分拆讓 B+L 業務受到更多關注,促使你們估值進一步重新評價(re-rating)的主要障礙之一,就是公司的槓桿水位。所以我想問,對公司而言,除了有機成長之外,尋找加速去槓桿化進程的方法有多高的優先順序?你們是否看到可行的途徑?

  • My second question was on the gross margin performance. We obviously saw very strong first half results. But I think as I look at the year, I think you averaged 73% the first half of the year. Your guidance is 72%. What's driving that step down in the second half? And maybe just some comments about how we should think about the gross margin trends over time given the 72% kind of baseline we're seeing in 2019?

    我的第二個問題是關於毛利率表現。我們顯然看到上半年結果非常強勁。但我看全年時,上半年平均大約是 73%。你們的指引是 72%。是什麼因素導致下半年出現這樣的下滑?另外,鑑於我們在 2019 年看到約 72% 這種基準水準,能否談談我們應如何看待毛利率長期趨勢?

  • Paul S. Herendeen - Executive VP & CFO

    Paul S. Herendeen - Executive VP & CFO

  • Sure. Thanks for the questions, Chris. It's Paul speaking. I mean you hit on the -- surely the primary way that we expected to delever is through growth of organic earnings and then prioritizing our -- the free cash flow generated to the reduction of debt. Certainly, there are -- we are now allocating more dollars to R&D. So we're not starving the business in order to be able to maximize cash flow in the short term but we are allocating R&D dollars in order to, as I said in my prepared remarks, ensure that we can drive organic growth over the much longer haul. That's the primary path that we are going to go down and that we will be sticking to.

    好的。謝謝你的提問,Chris。我是 Paul。你提到的重點沒錯——我們預期去槓桿的主要方式,確實是透過有機獲利成長,並將所產生的自由現金流優先用於償還債務。當然,我們現在也在研發上配置更多資金。因此,我們並不是為了短期最大化現金流而讓業務挨餓;相反地,我們投入研發資金,是為了——如同我在事先準備的發言中所說——確保我們能在更長期推動有機成長。這就是我們將採取並會持續堅持的主要路徑。

  • With respect to gross profit margin, we've communicated that in the first quarter, we put up a really strong number and we indicated that, that would not persist through the whole year and expected it to come down. And at that time, we maintained our guidance. We did put up a good strong first half. And so instead of having a range that I think it was in the lower end, was I think 71.5%. We said it's going to be circa 72% and that's reflective of we put a half year in the books and we continue to do well with our efforts to manage. You need to keep your eye on the LOEs that are going to hit in the second half. A total of over $200 million of LOEs that we expect to hit in the second half of the year and those are, by and large, very high-margin products that are from a mix perspective going to drive that down.

    至於毛利率,我們先前已溝通過:第一季我們繳出非常強勁的數字,並指出那樣的水準不會貫穿全年,預期會下滑。而在當時,我們維持了原先的指引。我們上半年確實表現強勁。因此,我們不再採用我記得下緣大約是 71.5% 的區間,而是表示將約為 72%,這反映出我們已完成半年的實績,且在管理相關工作上持續做得不錯。你需要留意下半年將發生的專利到期/獨占權喪失(LOE)。我們預期下半年將受到總計超過 2 億美元的 LOE 影響,而這些多半是高毛利產品,從產品組合(mix)角度將拉低毛利率。

  • Joseph C. Papa - CEO & Chairman of the Board

    Joseph C. Papa - CEO & Chairman of the Board

  • I think Paul did great job answering. The only thing I would say is complements to Paul and Will Woodfield, our treasurer who have just done a great job with our debt structure and given us this freedom to operate. As we generate cash, we're putting it towards either this debt payment or allowing us to look at some M&A opportunities. So to me, that's still the most important way we're going to reduce -- is grow our EBITDA to reduce our overall leverage. But good questions and good answers.

    我認為 Paul 的回答做得很好。我唯一想補充的是,要稱讚 Paul 以及我們的財務主管 Will Woodfield,他們在我們的債務結構上做得非常出色,讓我們有這樣的營運彈性。隨著我們產生現金,我們會把它用在償還債務,或是讓我們能夠評估一些併購(M&A)機會。所以對我而言,我們降低槓桿最重要的方式仍然是:透過成長 EBITDA 來降低整體槓桿比率。不過問題問得很好,回答也很好。

  • Operator

    Operator

  • The next question comes from the line of Akash Tewari of Wolfe Research.

    下一個問題來自 Wolfe Research 的 Akash Tewari。

  • Akash Tewari - Director of Equity Research & Senior Research Analyst

    Akash Tewari - Director of Equity Research & Senior Research Analyst

  • A few questions. So looking back at XIFAXAN in 2018, it was up 20% year-over-year. 1/3 of that was volume, 1/3 of that was Project CORE and 1/3 of that the price increase. By that math, you've been able to realize a pretty large amount of your WAC increases for XIFAXAN historically. And it looks like you've realized about 6% for the January increase recently. Do you have any comment on what's allowing you to do that and how we should think about the net realized price contribution on XIFAXAN going forward?

    有幾個問題。回頭看 XIFAXAN 在 2018 年的表現,年增 20%。其中 1/3 來自銷量、1/3 來自 Project CORE、另外 1/3 來自提價。照這樣算,你們過去在 XIFAXAN 的 WAC 調升上,歷來能實現的幅度其實相當大。而看起來你們最近對 1 月的調價大約實現了 6%。你們能做到這點的原因是什麼?以及我們應該如何看待未來 XIFAXAN 淨實現價格(net realized price)對營收貢獻的走勢?

  • Next, you've previously stated that your SIBO trials for XIFAXAN will be run via the 550 dose. Today's (inaudible) make that explicitly clear. What formulation will you use for your SIBO trials? And can you talk about the commercial opportunity for this indication over time?

    接著,你們先前曾表示 XIFAXAN 的 SIBO 試驗會以 550 劑量進行。今天的(聽不清)並沒有把這點說得非常明確。你們的 SIBO 試驗會使用哪一種劑型?另外,能否談談這個適應症隨時間推進的商業機會?

  • And then lastly, we noticed the corporate allocation for SG&A decreased from $86 million to $71 million year-over-year. Can you talk about what drove that decrease and how much operating leverage is there internally to reduce this corporate allocation spend over time?

    最後,我們注意到 SG&A 的公司分攤(corporate allocation)年減,從 8,600 萬美元降到 7,100 萬美元。能否談談是什麼因素導致這個下降?以及內部有多少營運槓桿可以在未來逐步降低這項公司分攤支出?

  • Paul S. Herendeen - Executive VP & CFO

    Paul S. Herendeen - Executive VP & CFO

  • Thanks, Akash. I see 3 really good questions. Let me start with the question around XIFAXAN and how we are able to improve that gross to net, which has the appearance of us gaining via price. If you look back at '18, we talked a lot about the steps that we took at the beginning of '18 in non-retail channels where we reduced some discounting that was just frankly not -- was not a great play by the prior regime to enter into those agreements. And when they came up at the beginning of 2018, we simply didn't renew and made better deals in non-retail channels.

    謝謝你,Akash。我看到三個非常好的問題。我先從 XIFAXAN 的問題開始,也就是我們如何改善 gross-to-net,而這看起來像是我們透過價格取得了增益。如果回頭看 2018 年,我們談了很多在 2018 年初於非零售通路所採取的措施:我們降低了一些折扣;坦白說,前一個管理團隊為了進入那些協議而給出的折扣並不是一個好策略。當那些協議在 2018 年初到期時,我們就不再續約,並在非零售通路談了更好的交易。

  • Those are clinics. Those are not hospitals. It's mainly clinics and other groups that buy directly, and that was a big driver through 2018 versus 2017. The other thing if you recall at the end of last year, we substantially suck down the pipeline inventory for all of our products and of course, XIFAXAN is a big product for us. That assisted us in improving our gross to net by not having the same requirement for accruals with respect to a product like XIFAXAN and not just XIFAXAN, but XIFAXAN, APRISO, UCERIS before it went generic, Glumetza, really across the board. But you specified XIFAXAN but it really was across the board that that helped as well. And we've continued that -- into 2019. And so as we clean things up, we are just getting the realization of a lift in gross to net, which is helpful.

    那些是診所。不是醫院。主要是診所和其他直接採購的團體,而這是 2018 年相較 2017 年的一個重要驅動因素。另外,如果你還記得,我們在去年年底大幅降低了所有產品的通路庫存(pipeline inventory),當然 XIFAXAN 是我們的重要產品。這也幫助我們改善 gross-to-net,因為對於像 XIFAXAN 這樣的產品,我們不再需要同樣程度的應計(accrual)要求;而且不只是 XIFAXAN,還包括 XIFAXAN、APRISO、在轉為學名藥之前的 UCERIS、Glumetza,基本上是全面性的。你特別點名 XIFAXAN,但其實這是全面性的改善,也同樣帶來幫助。而我們在 2019 年也持續推進這件事。因此,當我們把這些事情整理乾淨後,我們就能實現 gross-to-net 的提升,這是有幫助的。

  • We called out the impact of the January price increase because we certainly don't want to give the impression that that growth is a result of us raising prices in the system. What we're doing is we're better managing our gross to nets, not just for XIFAXAN but across the board with many of our products that's all part of that Project CORE. We've been quite successful with it. Joe, you want to take the SIBO trial?

    我們特別提到 1 月調價的影響,是因為我們當然不希望讓人以為這些成長是因為我們在體系中提高價格所造成的。我們在做的是更好地管理 gross-to-net,不只是 XIFAXAN,而是我們許多產品的全面管理,這都是 Project CORE 的一部分。我們在這方面相當成功。Joe,你要回答 SIBO 試驗的問題嗎?

  • Joseph C. Papa - CEO & Chairman of the Board

    Joseph C. Papa - CEO & Chairman of the Board

  • Sure. The only thing I want to say to the last part of what Paul said, too, is just on these coupon copay cards, we're just trying to be smarter about where we put those so that where we're putting them we're getting the gross to nets that we think are appropriate that are helping to grow the overall revenue. That's what Project CORE is all about. CORE stands for cost optimization revenue enhancement, and that's why we're doing it.

    好的。我也想補充 Paul 剛才最後一段提到的部分:關於這些折價券/共付額卡(coupon copay cards),我們只是想更聰明地決定投放在哪裡,確保投放的地方能帶來我們認為合適的 gross-to-net,並有助於推動整體營收成長。這就是 Project CORE 的核心。CORE 代表 cost optimization revenue enhancement(成本最佳化、營收提升),這也是我們推動它的原因。

  • On the question on the SIBO clinical trial, you are correct. We had previously talked about the 550-milligram dose on that. I think at this point, the best way I'll say is that we got some very interesting things going on with our SSD formulations with our controlled-release SSD or immediate-release SSD. We have some very interesting things going on with the [ERR] and then on additional formulations. So we're looking at a lot of different ways to try to improve on this. And importantly, not just to have a new formulation but to have better efficacy for the patient that needs the IBS-C or SIBO indication. So look for us to have more to say about that but I just want to let you know that we are not stopping just with what we have. We are looking at new ways to deliver XIFAXAN and get a better patient response on the efficacy side. So we'll have more to say about that when we actually launch the trial, but just know that we are investing behind XIFAXAN as our largest product and looking at all the opportunities in front of us for new formulations, Paul, do you want to take that last corporate SG&A comment?

    關於 SIBO 臨床試驗的問題,你說得沒錯。我們先前確實談過會用 550 毫克劑量。我想目前我能說的最好方式是:我們在 SSD 劑型方面有一些非常有意思的進展,包括我們的控釋 SSD 或速釋 SSD。我們在 [ERR] 以及其他額外劑型上也有一些非常有意思的進展。所以我們正在用很多不同的方法來嘗試改進。而且重要的是,不只是推出新劑型,而是要讓需要 IBS-C 或 SIBO 適應症的病患獲得更好的療效。所以請期待我們之後會有更多說明;但我想讓你知道的是,我們不會只停留在現有的做法。我們正在尋找新的方式來遞送 XIFAXAN,並在療效面取得更好的病患反應。等到我們真正啟動試驗時,我們會再多談一些;但請知道,我們正在加大對 XIFAXAN(我們最大的產品)的投資,並評估眼前所有新劑型的機會。Paul,你要回答最後關於公司 SG&A 的評論嗎?

  • Paul S. Herendeen - Executive VP & CFO

    Paul S. Herendeen - Executive VP & CFO

  • Yes, sure. I mean the corporate SG&A, I called out in my remarks, I think what we're doing is we're trying to be much more effective in the dollars that we deploy to what I'll call enabling activities. Those are noncustomer-facing activities back in the home office. And so overall, quarter-to-quarter, we were down $10 million, which is not a lot, but we are very focused on that, being efficient there.

    好的,當然。關於公司端 SG&A,我在發言中有提到:我們正在努力讓我們投入在我所稱的「賦能活動」(enabling activities)上的資金更有效率。這些是總部後端、非面向客戶的活動。因此整體來看,按季比較我們下降了 1,000 萬美元,這不算很多,但我們非常專注於在這方面提升效率。

  • I also did call out and point out that going the other way, we are investing more in our IT and IT infrastructure. This is an area that if you go back 4, 5, 6 years, as the company came together through a series of acquisitions, perhaps they -- we did not invest as much behind that as we might have if we'd been here then. We're fixing that now. We've put together a terrific team, and we're supporting them with funding that'll enable us. So you got that going up, and that's why I called it out. And -- but more importantly, the balance of our enabling functions, we're being as efficient as we can because unless somebody can tell me different, enabling functions typically don't drive revenue.

    我也確實提到並指出,反方向來看,我們正在加大對 IT 與 IT 基礎設施的投資。如果你回頭看 4、5、6 年前,當公司透過一連串併購整合在一起時,也許他們——我們在這方面的投入沒有像如果當時我們在場會做的那麼多。我們現在正在修正這件事。我們組建了一支非常出色的團隊,並以資金支持他們,讓我們具備相應能力。所以這一塊支出是上升的,這也是我特別點出的原因。但更重要的是,在其他賦能職能的平衡上,我們會盡可能提高效率,因為除非有人能說服我不然,賦能職能通常不會直接帶動營收。

  • Operator

    Operator

  • The next question comes from Umer Raffat of Evercore ISI.

    下一個問題來自 Evercore ISI 的 Umer Raffat。

  • Umer Raffat - Senior MD & Senior Analyst of Equity Research

    Umer Raffat - Senior MD & Senior Analyst of Equity Research

  • I had one for Joe and one for Paul if I may. Joe, would you be open to a large cash flow deal even if it's not exactly a growing asset, perhaps a bunch of assets in China, et cetera? Would you open to something like that? And while you're at it, can you quantify for us the size of your China business today and what percentage is Rx?

    如果可以的話,我有一個問題問 Joe,一個問題問 Paul。Joe,即使不是一個正在成長的資產,你是否也願意做一筆大型現金流交易,例如在中國的一籃子資產等等?你會考慮這樣的交易嗎?另外,能否為我們量化你們目前中國業務的規模,以及其中處方藥(Rx)占比是多少?

  • And Paul, I don't know how to ask, but I should ask anyway. The question is, I've kept getting questions on whether you may possibly consider retirement near term. So I was curious, have you looked into renewing your contract beyond August? Do you like still Joe? Do you still like Scott?

    Paul,我不知道該怎麼問,但我還是應該問。問題是,我一直被問到你是否可能在短期內考慮退休。所以我很好奇,你是否已經在研究把合約續到 8 月之後?你還喜歡 Joe 嗎?你還喜歡 Scott 嗎?

  • Joseph C. Papa - CEO & Chairman of the Board

    Joseph C. Papa - CEO & Chairman of the Board

  • We like Paul too much.

    我們太喜歡 Paul 了。

  • Paul S. Herendeen - Executive VP & CFO

    Paul S. Herendeen - Executive VP & CFO

  • Yes, that's a good one.

    是的,這個問得好。

  • Joseph C. Papa - CEO & Chairman of the Board

    Joseph C. Papa - CEO & Chairman of the Board

  • Let me start with the first question, and Paul, we'll give you time to contemplate your comment back. So Umer, on the question of large cash flow deals, I think the best way I can answer that is that we are driven to drive long-term shareholder value. We'll continue to think of all options that will drive that long-term shareholder value. So if it's the cash flow or other things, that's clearly something we always look at relative to anything that can help. And especially, if it's a large cash flow, that would allow us to improve our overall leverage and the business as we would grow EBITDA. So anything that we think has the opportunity to drive shareholder value, we would do that.

    我先從第一個問題開始,Paul,我們也會給你時間思考你要怎麼回應你的那段評論。所以 Umer,關於大型現金流交易的問題,我想我能給的最佳回答是:我們的驅動力是創造長期股東價值。我們會持續思考所有能夠推動長期股東價值的選項。所以不論是現金流或其他事項,這顯然都是我們一直會評估、看是否能帶來幫助的。尤其如果是大型現金流,將使我們能改善整體槓桿水準,並在我們成長 EBITDA 的同時強化業務。因此,任何我們認為有機會推動股東價值的事情,我們都會去做。

  • On the question of China, ballpark, our China business is approximately $400 million of sales. The majority of it is in obviously the eye care business. I'd remind you that we are the #1 player in contact lenses, we are the #1 player in eye drops in China as the 2 primary areas of our importance there.

    關於中國的問題,粗略來看,我們在中國的業務銷售額約為 4 億美元。其中大部分顯然是在眼科護理業務。我也提醒各位,我們在中國隱形眼鏡是第 1 名、眼藥水也是第 1 名,這兩個是我們在當地最重要的兩大領域。

  • Paul, do you want to answer your comment?

    Paul,你要回應一下你的那段評論嗎?

  • Paul S. Herendeen - Executive VP & CFO

    Paul S. Herendeen - Executive VP & CFO

  • Yes, sure. Yes, thanks for putting me on the spot there. When I joined, I mean it was -- the question was say, "Well, we want a contract." And we settled on a 3-year contract. Correct me if someone -- I'm looking at Christina, our General Counsel. I think it automatically renews and just keeps right on going. The last couple of years, the Comp Committee has seen fit to provide me with incremental incentives to stick around in terms of equity. So as long as I'm having fun and I feel like I'm adding value, I'm intending to stick around.

    好的,當然。是的,謝謝你把我逼到這個點上。我加入的時候,我是說——當時的問題是:「我們想要一份合約。」我們最後敲定的是一份 3 年期合約。如果有人要更正我——我在看 Christina,我們的總法律顧問。我想它會自動續約,然後就一直延續下去。過去幾年,薪酬委員會(Comp Committee)也認為適合提供我額外的誘因、以股權的方式讓我留下來。所以只要我還覺得有趣、也覺得自己在創造價值,我就打算繼續留下來。

  • Joseph C. Papa - CEO & Chairman of the Board

    Joseph C. Papa - CEO & Chairman of the Board

  • And you are adding value.

    而且你確實在創造價值。

  • Operator

    Operator

  • The next question comes from Annabel Samimy of Stifel.

    下一個問題來自 Stifel 的 Annabel Samimy。

  • Annabel Eva Samimy - MD

    Annabel Eva Samimy - MD

  • So wanted to ask about dermatology. DUOBRII clearly seems to be launching more rapidly than the others. Is it coming at the expense of the other psoriasis products? Are these launches now enough to offset some of the sizable pressure that you saw in this new dermatology environment? Do we get to see growth of the business again?

    我想問一下皮膚科業務。DUOBRII 顯然看起來比其他產品推出得更快。這是否是以其他乾癬產品為代價?這些新上市產品現在是否足以抵消你在這個新的皮膚科環境中看到的一些相當大的壓力?我們是否能再次看到業務成長?

  • And then if you could help us with Dermatology.com, with the addition of Walgreens, do you expect to see these increased volumes offset by pricing? Or do you now get the benefit of both volume and better pricing? And so just if you could just help us understand the dynamic there between the volume and the pricing.

    另外,關於 Dermatology.com,在加入 Walgreens 之後,你是否預期這些增加的量會被價格所抵消?還是你現在能同時享有量的提升與更好的定價?所以如果你能幫我們理解一下量與價格之間的互動關係。

  • Joseph C. Papa - CEO & Chairman of the Board

    Joseph C. Papa - CEO & Chairman of the Board

  • Okay. A lot of good questions there. First and foremost, we are very pleased with DUOBRII and what we're seeing over approximately 1,550 prescriptions per week. And if you see what we're able to do here, during the quarter, we were able to grow SILIQ versus a year ago. SILIQ was up approximately 267% versus last year. Sales have essentially doubled. So that's clearly going in the right direction during the quarter. The BRYHALI prescriptions are right around that 1,700 level. So it's still holding its own. So it's not coming, just simply replacing -- DUOBRII is not simply replacing BRYHALI. We're still able to hold BRYHALI as well.

    好的。這裡有很多好問題。首先也是最重要的,我們對 DUOBRII 以及我們看到的表現非常滿意,目前每週約 1,550 張處方。而且如果你看我們在這裡能做到的,在本季期間,我們讓 SILIQ 相較去年同期成長。SILIQ 相較去年約成長 267%。銷售額基本上翻倍。所以本季這顯然是朝正確方向前進。BRYHALI 的處方量大約也在 1,700 的水準附近。所以它仍然維持得不錯。因此這不是在犧牲——DUOBRII 並不是單純取代 BRYHALI。我們也仍然能維持 BRYHALI。

  • So we think that overall dermatology business is going in the right direction. We absolutely had some LOEs, as I mentioned on the call, that we had to work our way through. But overall, probably the best thing I can say about our dermatology business is the strength of DUOBRII and what it's doing for psoriasis patients, for the patient, for the physicians when they're prescribing, gives them new alternatives for topical, which is what most of them are looking for, for the treatment of psoriasis. And then importantly, our ability to help lower the cost to manage care, if patients can delay the need for biologics, are all the reasons why we think this is going to truly transform the business model for us in dermatology. And you're seeing it. You're seeing it when I put this slide together it showed how the new products plus the growth in Solta are today somewhere in that 45% to 50% of our overall business. That's really transformation as clearly as we can show it.

    所以我們認為整體皮膚科業務正朝正確方向前進。正如我在電話會議中提到的,我們確實遇到了一些專利到期(LOE),必須逐步消化。但整體而言,對我們皮膚科業務最好的描述大概是:DUOBRII 的強勁表現,以及它對乾癬患者、對患者本身、以及醫師在開立處方時所帶來的價值,為外用治療提供了新的替代方案,而這正是多數人治療乾癬時所尋求的。此外也很重要的是,我們能協助降低管理式醫療的成本;如果患者能延後使用生物製劑的需求,這些都是我們認為它將真正改變我們皮膚科業務模式的原因。而你也正在看到這一點。當我整理這張投影片時,它顯示新產品加上 Solta 的成長,如今約占我們整體業務的 45% 到 50%。這就是我們能呈現的、非常清楚的轉型。

  • On the second part of the Dermatology.com, having an additional 9,500 stores to be representing the Dermatology.com and have a place where we can have a situation where there's no issues of cash pay is what's going to happen there, number one. Number two, it gets a very predictable price for the patient, so there's no variations on that. They all get a very predictable price. There's no prior authorizations for -- the physician requires. That's clearly another important part of what we're trying to accomplish with our Dermatology.com. And of course, as we have these additional outlets, it gives us even more places where the patient -- it's more convenient for patients. So predictable access for patients, predictable price for patients, physicians get the formulation they prescribe, the branded formulation they prescribe, we think it's a winning combination, and we're adding more products to it for the future.

    至於 Dermatology.com 的第二部分,新增 9,500 家門市來代表 Dermatology.com,並提供一個不會有自費現金支付(cash pay)問題的情境,這是第一點。第二點,它能為患者帶來非常可預期的價格,因此不會有價格波動。每位患者都能得到非常可預期的價格。也不需要事前授權(prior authorization)——醫師所需要的。這顯然也是我們透過 Dermatology.com 想達成的另一個重要部分。當然,隨著我們增加這些通路據點,也讓患者有更多地點可選——對患者更便利。因此,對患者而言是可預期的取得途徑、可預期的價格;對醫師而言,能取得他們所開立的配方、他們所開立的品牌配方。我們認為這是個雙贏的組合,而且未來也會把更多產品加入其中。

  • Paul S. Herendeen - Executive VP & CFO

    Paul S. Herendeen - Executive VP & CFO

  • Yes. I mean it's Paul. I want to jump in on this as well. I want to recognize Bill Humphries and his team because yes, this is something new. This is not something that we said, "Oh, well, look, somebody else did it, and we're going to go out and do it." And I think that the progress that we're making, it's coming step by step by step. But at this point, we currently have 9 brands that we have in the cash model. We are targeting 13 to 15 by year-end and a bunch more are coming at some point beyond that. We've products like ALTRENO, ALDARA, Efudex, Locoid Cream, Retin-A. I'm not going to get them all because I can't remember them from -- just from memory.

    是的。我是 Paul。我也想補充一下。我想肯定 Bill Humphries 和他的團隊,因為沒錯,這是一個新的做法。這不是我們說:「喔,你看別人做了,我們也出去做。」我認為我們取得的進展,是一步一步、一步一步累積而來。但截至目前,我們在現金模式(cash model)下已經有 9 個品牌。我們的目標是在年底前達到 13 到 15 個,之後某個時間點還會再加入更多。我們有像 ALTRENO、ALDARA、Efudex、Locoid Cream、Retin-A 這些產品。我就不一一列完了,因為我沒辦法只靠記憶把它們全都想起來。

  • But Bill and his team and -- they've done a great job of conceiving this, putting in place the way that we can have a cash model that's effective, using it with Dermatology.com. And the addition of all those doors with Walgreens is absolutely a help in us making progress on this side. I think it's going to change the way some of these drugs are delivered to patients for the benefit of everybody.

    但 Bill 和他的團隊——他們在構思這件事、建立一套有效的現金模式並透過 Dermatology.com 來運作方面,做得非常出色。而 Walgreens 增加了那麼多門市據點,絕對有助於我們在這一端持續取得進展。我認為這將改變其中一些藥品交付給患者的方式,讓所有人都受益。

  • Operator

    Operator

  • The next question comes from Gregg Gilbert of SunTrust.

    下一個問題來自 SunTrust 的 Gregg Gilbert。

  • Gregory B. Gilbert - Analyst

    Gregory B. Gilbert - Analyst

  • I have a few. Paul, I want to make sure I understand the gross-to-net benefit on XIFAXAN and what you're suggesting going forward. Should we expect another 7 percentage point benefit in third quarter, something less in 4Q and then nothing thereafter? That's the first question.

    我有幾個問題。Paul,我想確認我是否理解 XIFAXAN 的毛到淨(gross-to-net)效益,以及你對未來的建議。我們是否應該預期第三季還會有另外 7 個百分點的效益、第四季少一些,之後就沒有了?這是第一個問題。

  • Secondly, on DUOBRII, Joe, obviously, you got a label that you were wishing for. But are payers in any way trying to limit refills or duration or would you not know yet?

    第二個,關於 DUOBRII,Joe,很明顯你拿到了你一直希望得到的標籤(label)。但付款方是否以任何方式試圖限制續配(refills)或用藥期間,還是你們目前還不清楚?

  • And then lastly, going back to the China question, are there any sort of dynamics that you'd like to highlight for us in terms of the structure and type of your business and good things and bad things going on in China that we should be aware of?

    最後,回到中國的問題,就你們業務的結構與類型而言,在中國有哪些你想特別提醒我們的動態?中國目前有哪些好事與壞事是我們需要留意的?

  • Paul S. Herendeen - Executive VP & CFO

    Paul S. Herendeen - Executive VP & CFO

  • Great. It's Paul. I'll take that first one. With respect to the gross nets on XIFAXAN, yes, we're -- I'm not going to guide and say, "Oh, it's 700 basis points in Q2 versus Q2 of 2018," and say what it will be in Q3. But I think it'll continue to be a strong benefit to the brand in Q3 and then significantly less in Q4 and beyond as we kind of put all of the improvements. We're lapping the improvements, and it just kind of goes away as a growth driver, and we'll -- then we'd be limited to what can we generate in terms of unit growth. I mean that -- the TRx growth is still high single digits, and the team, Mark McKenna and his group, are doing a great job there. And secondarily, there may be the opportunity for a little bit of price as well.

    好的。我是 Paul。我先回答第一個。關於 XIFAXAN 的毛到淨(gross nets),是的,我們——我不會提供指引說「2019 年第二季相較 2018 年第二季是 700 個基點」,然後再說第三季會是多少。但我認為第三季它仍會持續對品牌帶來強勁的正面效益,而到了第四季及之後,隨著我們把所有改善都納入後,效益會顯著減少。我們會進入「比較基期已包含改善」的狀態,因此它作為成長驅動因素就會逐漸消失;接下來我們就會受限於能在單位數量成長上產生多少。我的意思是——TRx 成長仍在高個位數,而團隊(Mark McKenna 及其團隊)在這方面做得非常好。另外,也可能還有一些小幅提價的機會。

  • Joseph C. Papa - CEO & Chairman of the Board

    Joseph C. Papa - CEO & Chairman of the Board

  • On the question on DUOBRII, I would first and foremost thank you for your comment on the label. I absolutely agree the label is truly outstanding. I'd invite everyone on the call to just take a look at the label and especially compare it to other previous high-potency corticosteroid labels. The most important comment I can say on the label, which I think is critical, is that for the first time, physicians can use a high-potency corticosteroid product in a combination with a retinoid that allows the physician to treat to clearance rather than be limited by a certain duration. We think that's a very important comment.

    關於 DUOBRII 的問題,我首先要非常感謝你對標籤的評論。我完全同意,這個標籤確實非常出色。我也邀請所有參與電話會議的人去看一下標籤,尤其是把它與其他先前的高效價皮質類固醇(high-potency corticosteroid)標籤做比較。我認為標籤上最重要、也最關鍵的一點是:這是第一次,醫師可以使用一個高效價皮質類固醇產品,並與一種維甲酸類(retinoid)合併,讓醫師能以「治療至清除(treat to clearance)」為目標,而不是受限於某個固定療程期間。我們認為這是一個非常重要的說明。

  • The second comment I'd offer on the question of managed care, we did a budget impact model in managed care that shows that for every million lives that are in a health regional plan, by putting DUOBRII on formulary, they can save between 1 million to 4.5 -- or $1 million to $5 million per year by putting DUOBRII on the formulary. And essentially, what -- the simplistic way that I would say that it allows the patients to use a topical product for a longer duration to potentially delay the need to go to a high-priced biologic, which may be in the $50,000 per patient per year type of range. So that's clearly, we think, the real benefit.

    第二點,針對醫療保險管理(managed care)問題,我們在 managed care 中做了一個預算影響模型(budget impact model),顯示對於每 100 萬名納入某個區域健康計畫的人口而言,將 DUOBRII 納入處方集(formulary),每年可節省約 100 萬到 450 萬——或每年 100 萬到 500 萬美元的費用。本質上——用最簡單的方式來說,它讓病人能更長時間使用外用產品,從而可能延後需要使用高價生物製劑(biologic)的時間;而生物製劑的費用可能落在每位病人每年 50,000 美元左右的區間。因此我們認為,這顯然就是其真正的效益。

  • We haven't seen any limitations on refills at this time. I wouldn't expect that because the reality is, for every time a managed care plan keeps the patient on DUOBRII, that's one less patient potentially that would extend or go towards a biologic, which some patients are going to need biologic, but clearly, we think often we'd be able to keep patients at a much lower cost of therapy. We're talking in the range of $50,000 for the biologic, less than 1/10 of that for the DUOBRII.

    目前我們尚未看到對續配有任何限制。我也不預期會有,因為現實是:managed care 計畫每多一次讓病人留在 DUOBRII 上,就可能少一位病人需要延伸或轉向生物製劑;當然有些病人仍會需要生物製劑,但我們清楚地認為,很多情況下我們能以更低的治療成本讓病人維持治療。我們談的是:生物製劑大約 50,000 美元,而 DUOBRII 的成本不到其 1/10。

  • On the question of China dynamics, I think I would simply say that China clearly is the biggest -- well, the #1 player in the overall contact lenses business. Ballpark, looking at the Vision Care business and contact lenses, it's about 1/4 of the business for us is coming out of China as a percentage of our overall Vision Care business. So clearly, it's important to us. But I think relative to our eye drops, the other -- that's the other place we're #1 in China. So we feel very good about both of them.

    關於中國動態的問題,我想我會簡單說:中國顯然是整體隱形眼鏡業務中最大的——也就是排名第 1 的市場。粗略來看,以 Vision Care 業務與隱形眼鏡而言,我們整體 Vision Care 業務中約有 1/4 來自中國。所以很明顯,這對我們很重要。但相較於我們的眼藥水,另外——那也是我們在中國排名第 1 的領域。因此我們對這兩塊業務都感到非常有信心。

  • And we don't see any real big -- it's not exactly part of your question, but I will say, we don't see any major constraints that's happening at this time based on all of our production for the eye drops is based in China. And so we're producing in -- locally in China.

    而且我們沒有看到任何真正重大的——這不完全是你問題的一部分,但我會補充:就目前而言,我們沒有看到任何重大限制;因為我們所有眼藥水的生產都設在中國。因此我們是在中國本地生產。

  • Paul S. Herendeen - Executive VP & CFO

    Paul S. Herendeen - Executive VP & CFO

  • Yes. And you mean -- so you probably saw it, Gregg. It's Paul again. You probably saw the [action with the one] recently. And I'd just point out, that's all taken into account in our guidance. It certainly was not helpful to us, but it's all baked into our guidance as well.

    是的。你的意思是——所以你可能也看到了,Gregg。又是 Paul。你可能最近看到了那個[action with the one]。我只想指出,這些都已經納入我們的指引之中。它當然對我們沒有幫助,但也同樣已經完全反映在我們的指引裡。

  • And the other thing I'd say that is good is when people think about tariffs and the trade situation is a good chunk of -- again, to re-buttress the point, a good chunk of our lenses are manufactured in Waterford, Ireland, and we have our consumer facility, our sister facility to our other facility in the U.S., we have in Milan that can supply product to China.

    另外我想說的一個好消息是:當人們談到關稅與貿易情勢時,有相當一部分——再次強化這個觀點——我們相當一部分鏡片是在愛爾蘭沃特福德(Waterford, Ireland)製造;而且我們在米蘭有一個消費品工廠,也就是我們在美國另一個工廠的姊妹工廠,可以供應產品到中國。

  • So while we are impacted, it's all taken into account within our guidance, and it's been manageable so far. I guess we can't forecast how much worse it could get, but so far, so good.

    所以雖然我們確實受到影響,但這些都已納入我們的指引之中,而且到目前為止是可控的。我想我們無法預測情況可能會惡化到什麼程度,但目前為止一切都還不錯。

  • Operator

    Operator

  • The next question comes from Jason Gerberry of Bank of America.

    下一個問題來自美國銀行(Bank of America)的 Jason Gerberry。

  • Jason Matthew Gerberry - MD in US Equity Research

    Jason Matthew Gerberry - MD in US Equity Research

  • A couple here. So just first, maybe, Joe, what's the -- I realize it's early, but what's the general opportunity in your mind for amiselimod in the S1P space just given there are a number of competitors ahead of you aiming to improve upon the CV safety profile of different drugs in that class?

    這裡有幾個。首先,Joe,雖然我知道還很早,但就你看來,考量到在 S1P 領域已有多個競爭者領先、並試圖改善該類藥物不同產品的心血管(CV)安全性特徵,你認為 amiselimod 在 S1P 領域的整體機會是什麼?

  • And then my second question. Just thinking about the Significant Seven sales and guidance for the full year, can you talk a little bit -- it looks like there's about $100 million in first half revenues generated by Sig Seven products. How do you think about that Seven -- that second half step-up? Is it mainly just DUOBRII? Or are you expecting to get good revenue conversion on DUOBRII in the back half?

    然後第二個問題。就「Significant Seven」的銷售與全年指引來看,你能否談談——看起來 Significant Seven 產品在上半年大約產生了 1 億美元的營收。你如何看待下半年那個「七項」的增量(step-up)?主要只是 DUOBRII 嗎?還是你預期 DUOBRII 在下半年會有良好的營收轉換?

  • Joseph C. Papa - CEO & Chairman of the Board

    Joseph C. Papa - CEO & Chairman of the Board

  • Okay. So a couple of good questions here. Amiselimod, we think it's an important opportunity for us. We absolutely understand that there's a cardiovascular question that we are going to address. We are going to address it with a Holter study, a Q3 study that we are going to start and get accomplished by approximately end of the year. So we'll get that -- either positive or negative, we'll get that answered -- question answered very quickly and get that behind us so that we can go forward.

    好的。這裡有幾個不錯的問題。Amiselimod,我們認為對我們而言是一個重要的機會。我們完全理解有一個心血管方面的問題需要處理。我們將透過一項 Holter 研究來處理,也就是我們將在第三季啟動並在大約年底前完成的一項研究。因此我們會——不論結果是正面或負面——很快把這個問題回答清楚,並把它拋在身後,讓我們可以繼續往前推進。

  • On the area of what we view in terms of a benefit of amiselimod, we clearly believe that it has a longer half-life, which could equal better dosing. But we've obviously got to do the Phase II trial that we talked about to try to find out what exactly the opportunity is for us there.

    就我們所認為 amiselimod 的效益面向而言,我們清楚地相信它具有較長的半衰期,這可能等同於更佳的給藥方式。但我們顯然必須進行我們先前談到的第二期試驗,以嘗試釐清對我們而言究竟有哪些具體機會。

  • On the question of Significant Seven and 2019 guidance, we feel very good about where we are. First half, approximately $120 million or thereabout and -- but more importantly, accelerating up 76% versus the first half of 2018. So we think we're right on the right track to be approximately $300 million. So we need to grow a little faster, but clearly, we are right on track with what we expect for the launches especially now that we've got DUOBRII in the marketplace, the AQUALOX product in Japan. So all of them are now launched and going in the right direction. Very pleased with the results.

    關於 Significant Seven 與 2019 年財測指引的問題,我們對目前的進展感到非常有信心。上半年約 1.2 億美元左右——但更重要的是,相較於 2018 年上半年加速成長 76%。因此我們認為,我們正走在正確的軌道上,朝約 3 億美元邁進。所以我們需要再快一點成長,但很明顯地,就我們對各項上市產品的預期而言,我們完全在軌道上,特別是現在 DUOBRII 已在市場上推出,以及日本的 AQUALOX 產品。因此它們現在都已上市,並朝正確方向發展。我們對結果非常滿意。

  • Operator

    Operator

  • The next question comes from David Risinger of Morgan Stanley.

    下一個問題來自摩根士丹利(Morgan Stanley)的 David Risinger。

  • Zhu Shen Ng - Research Associate

    Zhu Shen Ng - Research Associate

  • It's Zhu Shen on for David Risinger. Two quick questions today. Could you please discuss the Vision Care business momentum going into the second half, including key drivers ahead? And could you also talk about some of the cash flow swing factors to note in the second half?

    我是代替 David Risinger 提問的 Zhu Shen。今天有兩個簡短問題。請問您能否談談視力保健(Vision Care)業務在下半年進入時的動能,包括接下來的關鍵驅動因素?另外,您也能談談下半年現金流變動需要注意的一些因素嗎?

  • Joseph C. Papa - CEO & Chairman of the Board

    Joseph C. Papa - CEO & Chairman of the Board

  • Okay. I'll take there first Vision Care, and Paul can do the cash flow. Clearly, what's happening in our Vision Care business, we have very strong growth with our Biotrue, with our ULTRA, so it's new products generated. But if you look at the data that we've presented in the chart, you can see quickly that we are outgrowing the market. If you look at our performance in the U.S., Bausch + Lomb contact lenses being up approximately 13%, market being up about 8%, just globally Bausch + Lomb being up about 8% versus market up about 5%. So clearly, we are taking share mostly behind the success of our new products as being the #1 factor.

    好的。我先回答視力保健的部分,現金流由 Paul 來說明。很明顯地,在我們的視力保健業務方面,Biotrue 與 ULTRA 帶來非常強勁的成長,因此主要是新產品所帶動。但如果你看我們在圖表中呈現的數據,你可以很快看到我們的成長速度超越市場。以美國市場來看,Bausch + Lomb 隱形眼鏡約成長 13%,市場約成長 8%;就全球而言,Bausch + Lomb 約成長 8%,而市場約成長 5%。因此很明顯地,我們正在取得市占,主要是因為新產品成功所帶動,這是第一大因素。

  • Longer term, though, I've got to repeat this because I think it's truly environmentally a big issue, there is a mega trend that the incidence of myopia is continuing to climb. Unfortunately, we all spend too much time -- those of you who have got 4 screens in front of you right now and looking at your phone and computers. We're spending a lot of time on screens, and even kids are spending time on computers, iPads, et cetera. That is, we believe, one of the problems: less time outside. This market -- this myopia epidemic is something that is real. You can't see a doubling of myopia in 40, 50 years and call it genetic. It has to be environmental, and we think it's the screen time and time kids spend indoors with video games versus outdoors playing with sporting activities. So we think it's real. We think it's going to be a mega trend that's going to continue to drive it. And I'm delighted to say that as we look at myopia and our work, we have over $100 million of product sales, not including the lenses, directed towards helping to try to improve the lives of patients with myopia.

    不過從長期來看,我必須再重申一次,因為我認為這確實在環境層面是一個重大議題:近視發生率持續攀升是一個巨大的趨勢。不幸的是,我們都花太多時間——你們當中現在有些人面前可能同時有 4 個螢幕,還在看手機與電腦。我們花很多時間在螢幕上,甚至孩子也花時間在電腦、iPad 等等。我們相信這是問題之一:戶外時間變少。這個市場——這場近視流行病是真實存在的。你不可能在 40、50 年內看到近視倍增,還把它稱作遺傳因素。它必然是環境因素,我們認為就是螢幕時間,以及孩子待在室內玩電玩、相較於到戶外從事運動活動的時間。所以我們認為這是真實的。我們認為這將是一個會持續推動的巨大趨勢。我也很高興地說,當我們檢視近視以及我們的相關工作時,我們有超過 1 億美元的產品銷售(不包含鏡片),是用來協助改善近視患者的生活。

  • So we are very excited about what we think the opportunity for us with the most integrated eye care platform we have on how we can help these patients.

    因此,對於我們擁有最整合的眼科照護平台,以及我們能如何協助這些患者,我們對此機會感到非常振奮。

  • Paul, do you want to take the second part about cash flow?

    Paul,你要不要回答第二部分關於現金流的問題?

  • Paul S. Herendeen - Executive VP & CFO

    Paul S. Herendeen - Executive VP & CFO

  • Sure. As I mentioned, we have our guidance that we expect to have cash flow from -- generated from operations in the range of $1.5 billion to $1.6 billion for the year. If you're thinking about the second half of the year, I'll call your attention to a couple of those slides. It's the other financial information. If you look at it year-to-date and compare that back to the guidance, a couple of things to point out. The contingent consideration and milestones year-to-date were $22 million. Full year is expected to be $50 million. The restructuring/other is $32 million. So far year-to-date is expected to be $50 million. So a little bit more to come. CapEx is actually weighted towards the second half of the year. We are $109 million through June 30. The guidance was for $275 million. So that's a fair amount more. And that is reflective of us continuing to ramp up the activities for the production of daily silicone hydrogel lenses for launch in the U.S. and also in other markets as well.

    當然。如我提到的,我們的指引是預期全年由營運所產生的現金流在 15 億至 16 億美元的區間。如果你在思考下半年,我想請你注意其中幾張投影片。也就是「其他財務資訊」。如果你看年初至今並與指引相比,有幾點需要指出。年初至今的或有對價與里程碑付款為 2,200 萬美元。全年預期為 5,000 萬美元。重整/其他為 3,200 萬美元。截至目前年初至今預期為 5,000 萬美元。所以後續還會再多一些。資本支出(CapEx)實際上偏重在下半年。截至 6 月 30 日我們已支出 1.09 億美元。指引為 2.75 億美元。所以還有相當多的支出。這反映出我們持續加速推進每日拋矽水膠鏡片的生產活動,以便在美國以及其他市場上市。

  • So those are the ones I would call out. I'll say it again, though, remember that Q3 is a -- should be a stronger cash flow quarter because of less interest that settles during Q3, and then Q4 is a little weaker because of interest that settles in Q4. So those are the things I'd point out from a cash flow perspective.

    以上是我會特別點出的項目。不過我再說一次,請記得第三季——由於第三季結算的利息較少,第三季應該會是現金流較強的一季;而第四季則會稍弱,因為有在第四季結算的利息。所以從現金流角度來看,以上是我會指出的重點。

  • Operator

    Operator

  • The next question comes from David Amsellem of Piper Jaffray.

    下一個問題來自 Piper Jaffray 的 David Amsellem。

  • David A. Amsellem - MD and Senior Research Analyst

    David A. Amsellem - MD and Senior Research Analyst

  • I had a question on consumer eye care. So on LUMIFY, nice growth in market share. I wanted to get your thoughts on where you think peak share can go here. I mean there's several other competitors. There's also private label. So where does this product, in your view, go in terms of its share? And also, if -- I may have missed this, if can you give us what the net sales were on LUMIFY for the second quarter?

    我有一個關於消費者眼部護理的問題。關於 LUMIFY,市占率成長不錯。我想聽聽你們對於你們認為這裡的市占率峰值可能到哪裡的看法。我的意思是,還有好幾個其他競爭對手。也有自有品牌(private label)。所以就你們的觀點,這個產品在市占方面會走到哪裡?另外,如果——也許我漏聽了——你們能否提供 LUMIFY 第二季的淨銷售額是多少?

  • And then second part of the question is just on e-commerce. You cited e-commerce growth for the product. I'm wondering if you can elaborate on how you're thinking about e-commerce broadly for the consumer eye care portfolio and how much of that is factored into your expectations for growth over the next few years.

    然後問題的第二部分是關於電商。你們提到該產品的電商成長。我想知道你們能否進一步說明,你們如何更廣泛地看待消費者眼部護理產品組合的電商策略,以及未來幾年成長預期中有多少已將電商因素納入考量。

  • Joseph C. Papa - CEO & Chairman of the Board

    Joseph C. Papa - CEO & Chairman of the Board

  • So you got a lot of questions there, and I'll try to hit them all. But where do I think LUMIFY is going, I'd start with a very simple metric. We believe we have the best product for patients that need a product like LUMIFY for redness relief in that we deal with, from a patient point of view, a product that does not restrict the arterial blood flow to the eye. It's a -- it deals with the venous blood flow, which I don't know about how you feel, but if I was -- had a family member or a friend, I'd always not want to restrict arterial blood flow to someone's eyes. So we think we have a better way of treating this than any other product out there, bar none. That's why we think we're getting the #1 recommendation from physicians to use LUMIFY. So that, we think, is going to be an important driver of our future success.

    你問了很多問題,我會盡量全部回答。至於我認為 LUMIFY 會走到哪裡,我會先從一個非常簡單的指標開始。我們相信,對於需要像 LUMIFY 這類用於緩解眼紅的患者而言,我們提供的是最佳產品;從患者角度來看,這是一種不會限制眼部動脈血流的產品。它——它作用於靜脈血流;我不知道你怎麼想,但如果是我的家人或朋友,我一定不希望去限制某人的眼部動脈血流。因此我們認為,我們在治療這個問題上比市面上任何其他產品都更好,無出其右。這也是為什麼我們認為醫師對使用 LUMIFY 的推薦度排名第一。因此我們認為,這將會是我們未來成功的一個重要驅動因素。

  • The revenue in the quarter, ballpark of over $11 million was the revenue from LUMIFY in the quarter. So we're very pleased with where that's going and the direction of the growth there for us on LUMIFY.

    本季營收約略超過 1,100 萬美元,這部分營收來自本季的 LUMIFY。因此,我們對 LUMIFY 目前的進展以及其成長方向感到非常滿意。

  • On the question of e-commerce broadly, we think that the team led by Joe Gordon is just doing an outstanding job and also Tom Appio internationally on what we are doing with our overall consumer business. The 2 of them have come up with programs and initiatives both here in the United States and globally to help drive our business. I mean if you look at the performance of PreserVision, Ocuvite, those vitamins are doing very strong. And we think that's how -- a large part of it's tied to this need for better products for ocular -- eye health.

    關於整體電商的問題,我們認為由 Joe Gordon 領導的團隊表現非常出色;此外,Tom Appio 在國際市場上推動我們整體消費者業務的工作也同樣出色。他們兩位在美國本土以及全球都提出了多項方案與倡議,以協助帶動我們的業務。我的意思是,如果你看 PreserVision、Ocuvite 的表現,這些維他命產品的表現非常強勁。我們認為其中很大一部分與市場對更佳眼部—眼睛健康產品的需求相關。

  • So that's what we're planning to do. We're planning to launch more of the line extension. To be absolutely clear, we've launched LUMIFY but look to us to look at not just LUMIFY treating redness in the eye but also putting a combination product out there with LUMIFY plus either an antihistamine or other product to make sure that we not only help the redness but also the allergic eye. So look to us to come with more things in the future that help expand this category and help us to grow it beyond where it is today.

    所以這就是我們的規劃。我們計畫推出更多的產品線延伸。為了說得非常清楚,我們已推出 LUMIFY,但請期待我們不僅讓 LUMIFY 用於治療眼睛泛紅,也會推出複方產品,例如 LUMIFY 加上抗組織胺或其他產品,以確保我們不僅改善泛紅,也能處理過敏性眼部問題。因此,未來請期待我們推出更多產品,以協助擴大此品類,並推動其成長超越目前的規模。

  • Paul S. Herendeen - Executive VP & CFO

    Paul S. Herendeen - Executive VP & CFO

  • Yes, it's Paul. Just a couple of factoids on the consumer business. I mean that consumer business is -- if you think about in relation to our entire business, it's like 17%, 18% of our total business. It is the largest contributor to the B+ L/International segment, very important segment to us and, I think, being really well run by Tom Appio internationally and Joe Gordon in the U.S. So we are really doing well.

    是的,我是 Paul。補充幾個關於消費者業務的小數據。我的意思是,若相對於我們整體業務來看,消費者業務約占我們總業務的 17%、18%。它是 B+L/International 部門中最大的貢獻來源,對我們而言是非常重要的部門;而且我認為在國際市場由 Tom Appio、在美國由 Joe Gordon 的管理都非常到位。所以我們的表現確實很好。

  • Operator

    Operator

  • The last question for today will come from Louise Chen of Cantor.

    今天最後一個問題將由 Cantor 的 Louise Chen 提出。

  • Louise Alesandra Chen - Senior Research Analyst & MD

    Louise Alesandra Chen - Senior Research Analyst & MD

  • So first question I had was with respect to capital allocation. I was wondering if you could give us an update on what you're thinking there. And then second question was just on the timing of new opportunities for XIFAXAN. I know you talked about it earlier, but just curious if you could give us some timing. And then last one is just on TRULANCE. When do you see this increased promotional asset really hitting its stride? And what do you think peak sales for this product could be?

    我第一個問題是關於資本配置。我想請問你們能否更新一下目前的思考方向。第二個問題是關於 XIFAXAN 新機會的時程。我知道你們先前有提到,但想了解更具體的時間點。最後一個問題是關於 TRULANCE。你們預期這項加強推廣的資產何時會真正進入最佳狀態?你們認為這個產品的峰值銷售額可能是多少?

  • Joseph C. Papa - CEO & Chairman of the Board

    Joseph C. Papa - CEO & Chairman of the Board

  • Paul, you want to take the capital allocation portion first?

    Paul,你要先回答資本配置的部分嗎?

  • Paul S. Herendeen - Executive VP & CFO

    Paul S. Herendeen - Executive VP & CFO

  • Sure. Yes, I'll start on the capital allocation. I mean first, you see it in our results. I mean we are spending more in R&D, and that's a function of us and -- now that we have our legs under us ensuring that we can drive organic growth here into the future. So we're increasing our spend in R&D. We are increasing our spend in CapEx, which in the Vision Care business is kind of another form of R&D.

    當然。是的,我先談資本配置。首先,你可以從我們的業績結果中看到。我的意思是,我們在研發(R&D)上的投入增加了,這反映出我們—現在已站穩腳步—正確保能在未來推動內生成長。因此我們提高研發支出。我們也增加資本支出(CapEx);在視力照護業務中,這某種程度上也可視為另一種形式的研發。

  • If you think about what's left over after when you have free cash flow, the waterfall is prioritize debt, reduction of debt owing to our high leverage. And then secondarily, if there are opportunities where we can tuck in acquisitions that fit right on top of our core businesses, we would very seriously entertain that. I think you saw that with the TRULANCE acquisition earlier this year. But it's pretty straightforward. We're investing in our business, and then to the extent that we generate cash, we're using that to repay debt. And then if we see greater opportunity, we'll go ahead and take advantage of that for business development in our core areas.

    如果你思考在自由現金流之後還剩下什麼,我們的資金運用順序(waterfall)是:優先處理債務、降低債務,因為我們的槓桿偏高。其次,如果有機會進行能直接補強我們核心業務的補強型併購(tuck-in acquisitions),我們會非常認真地評估。我想你們今年稍早看到我們收購 TRULANCE 就是例子。整體來說相當直接。我們投資於自身業務,並在產生現金的情況下用於償還債務。若看到更大的機會,我們也會在核心領域的業務發展上把握機會。

  • Joseph C. Papa - CEO & Chairman of the Board

    Joseph C. Papa - CEO & Chairman of the Board

  • And then under the second part of your question, the timing for the new opportunities on XIFAXAN, rifaximin we look to have the OHE -- acute OHE study in the end of this year. In terms of getting data from that, I remind you that there's approximately 156,000 hepatic encephalopathy hospitalizations that -- and growing in number. So clearly, it's an important opportunity. But most importantly, that will also just give us some good indications for dosing on the SSD opportunity.

    接著是你第二個問題,關於 XIFAXAN(rifaximin)的新機會時程:我們預計在今年年底進行 OHE—急性 OHE 研究。至於取得該研究數據的時間點,我提醒各位,大約有 156,000 例肝性腦病變住院案例—而且數量仍在增加。因此,這顯然是一個重要機會。但更重要的是,這也將為我們在 SSD 機會上的劑量設定提供一些良好的指引。

  • Beyond that, we talked about the SIBO patient enrollment beginning in the first quarter of 2020. That's always -- and they're a good opportunity for us. That's going to be predominantly a Phase II trial to give us some more information on dose ranging. But we expect that's a couple of years away, 2, 3 years away, for actual clinical trial results in terms of actually being able to have an opportunity to get an approval or something like a SIBO trial. But remind you that the big opportunity with the SIBO trial is there's 17 million patients in the United States with IBS-C. There's actually -- when you think about SIBO, it's just an important opportunity in terms of the total number of patients out there.

    除此之外,我們也提到 SIBO 的病患收案將於 2020 年第一季開始。那一直—而且對我們而言是個不錯的機會。這將主要是一項第二期(Phase II)試驗,以提供更多關於劑量範圍(dose ranging)的資訊。但我們預期距離實際臨床試驗結果大約還要 2 到 3 年,才能在 SIBO 試驗這類項目上有機會取得核准或類似的成果。不過提醒各位,SIBO 試驗的重大機會在於:美國有 1,700 萬名 IBS-C 病患。實際上,當你想到 SIBO 時,就會發現就整體病患人數而言,這是一個重要機會。

  • And then we also have a trial for postoperative Crohn's. That's about 780,000 patients with Crohn's disease. About 75% of them will need surgery in their lifetime, and unfortunately, about 70% will have recurrence of symptoms within 1 year. We view that as a trial that we will start in the first half of 2020. We think that's approximately a 3-year duration to get to something like approval approximately in terms of the time frame. So we're really excited about where we're going with the XIFAXAN trials. We think there's some great opportunities for it.

    另外,我們也有一項針對術後克隆氏症(postoperative Crohn's)的試驗。約有 780,000 名克隆氏症患者。其中約 75% 在一生中會需要手術,而不幸的是,約 70% 會在 1 年內症狀復發。我們認為這是一項將於 2020 年上半年啟動的試驗。我們認為其期程約為 3 年,才能在時間框架上推進到類似取得核准的階段。因此,我們對 XIFAXAN 試驗的進展方向感到非常振奮。我們認為它有一些很棒的機會。

  • On the final question on TRULANCE, I always say that for any new sales force, when they take up a new product, they have usually 3 to 6 months to hit the ground running. But I will say for us, what we believe we now have is the best IBS platform. If it's IBS-C, IBS-D, together with what we have with XIFAXAN plus TRULANCE, we believe the sales reps can hit the ground very quickly. These are the same sales reps that have just done an outstanding job in primary care and the growth of IBS-D. So I would always say 3 to 6 months to gain traction, but between us, I'm excited to see that -- this is a great team. They've done great things in the past. I look forward to seeing their results in the future.

    至於最後一個關於 TRULANCE 的問題,我一向會說,任何新的銷售團隊在接手新產品時,通常需要 3 到 6 個月才能迅速上手、全面展開。但我想說,對我們而言,我們相信我們現在擁有的是最佳的 IBS 平台。無論是 IBS-C、IBS-D,結合我們的 XIFAXAN 加上 TRULANCE,我們相信業務代表可以非常快就進入狀況。這些都是同一批在基層醫療(primary care)以及 IBS-D 成長方面表現非常出色的業務代表。所以我通常會說需要 3 到 6 個月來建立動能,但私下說,我很期待看到—這是一支很棒的團隊。他們過去做出很好的成績。我也期待看到他們未來的成果。

  • Operator, that concludes our comments for today. I thank everyone for joining us today and look forward to hearing any additional questions that you may have in the near future. But thank you for joining us. Have a great day, everyone.

    接線員,以上是我們今天的發言。感謝各位今天參與,也期待在不久的將來聽到各位可能提出的其他問題。再次感謝各位加入。祝各位今天愉快。

  • Operator

    Operator

  • The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.

    本次電話會議到此結束。感謝各位參加今天的簡報。您現在可以掛線。